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 Genome integrity is constantly affected by DNA damage and replication errors due 
to exogenous and endogenous sources. Cells have developed several strategies to counteract 
these threats detecting DNA damages and mediating its repair through different mechanisms 
depending on the specificity of the DNA lesion. 
Cancer cells are more sensitive to these insults compared to normal cells and most therapeutic 
strategy indeed rely on inducing specific lethal DNA damages. The urgent need for new 
therapeutic strategies in cancer treatment is due to the frequent development of resistance to 
therapeutic induced DNA damage. 
 Through a multidisciplinary project, comprising a computational, a synthetic, a biology 
as well as a biophysical contribution, we aim at applying a synthetic lethality approach in cancer 
cell therapy by preventing, with small molecules, the viable hRAD51-BRCA2 interaction. 
The latter interaction plays a key role in the repair of double strand breaks (DSBs) within the 
homologous recombination (HR) pathway. 
The leading idea of our project is mimicking the synthetic lethality induced in BRCA2 
defective oncology patients by olaparib, a poly ADP ribose polymerase (PARP) inhibitor. We 
aim at increasing cancer cells sensitivity to PARPi and at broadening PARPi applicability by 
administering, in combination with the latter inhibitors, hRAD51-BRCA2 small molecules 
disruptors also to individuals without BRCA2 mutations. 
 The goal of my PhD research project is the characterization of the hRAD51-BRCA2 
interaction through a biophysical approach, in order to gain kinetic and thermodynamic insights 
on this critical junction of the HR pathway, and through a structural approach, to elucidate the 
atomic details of the interaction. My research work is concurrently a critical support for the 
overall project, which aims at the development of a new drug and at the validation of a broaden 
applicability of the synthetic lethality concept.
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Chapter one
1Introduction 
 Genome integrity is constantly affected by DNA damage and replication errors due to 
exogenous and endogenous sources. Physical or chemical agents are the most common cause of 
environmental DNA damage. Ionizing radiations (IR) and ultraviolet (UV) light are examples 
of physical genotoxic agents. IR can induce oxidation of DNA bases and cause single strand 
or double strand DNA breaks (SSB or DSB), while UV can induce up to 105 DNA lesions per 
cell per day1 generating pyrimidine dimers and pyrimidine (6-4) pyrimidone photoproducts. 
Chemical agents used in chemotherapy can also generate several DNA lesions depending on 
their mechanism of action: alkylation of DNA bases (i.e. temozolomide), intra or interstrand 
crosslinks, linking bases of the same or of different DNA strands respectively (i.e. cisplatin), 
SSB or DSB, locking the formation of topoisomerase-DNA covalent cleavage complexes (i.e. 
etoposide). 
 Cells have actually already developed DNA repair mechanisms to retrieve specific types 
of DNA errors and lesions. The DNA damage response (DDR) is a complex transduction pathway 
that senses replication stress and DNA damage in order to counteract these genome integrity 
threats2,3. Cells are provided with all the enzymatic tools (nuclease, helicases, polymerases, 
topoisomerases, recombinases, ligases, glycosylases, demethylases, kinases and phosphatases) 
required to remodel and repair DNA. Nonetheless, their activities must be regulated in a 
spatiotemporal way to prevent the formation of deleterious DNA structures during physiological 
cellular processes. Eukaryotic cells have developed specific strategies to recruit the right factors 
in the right place at the right time. Cells present different mechanisms of DNA repair depending 
on the type of DNA lesion involved (Figure 1.1). Mismatch repair (MMR) corrects mispaired 
DNA bases, while base excision repair (BER) acts through the excision of the damaged bases4,5. 
Nucleotide excision repair (NER) removes both pyrimidine dimers and intrastrand crosslinks 
1.1 The DNA damage response (DDR)
2Figure 1.1: DDR pathways and cell cycle targets. (Taken from O’Connor et al.9).
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removing an oligonucleotide of 30 base pairs (bp) containing the damaged site or excising the 
interstrand crosslink with the help of proteins involved in the Fanconi anemia syndrome1,6, 
respectively. Single strand break repair (SSBR)7 and double strand break repair (DSBR) repair 
SSB and DSB, respectively. Regarding DSBs, they can be restored by two different pathways: 
non homologous end joining (NHEJ) that promotes the potentially inaccurate relegation of 
DSBs, and homologous recombination (HR) that provides an error free mechanism of repair8.  
31.1.1 The signal transduction: sensors, mediators and effectors
 Upon a DNA lesion, the activation of the pathways involved in sending an SOS to initiate 
the repair of the damage by the cell is fundamental. The signal transduction mediated by the 
DDR occurs through the action of sensors, mediators, transducers and effectors. This regulatory 
pathway is well conserved in mammals; indeed, homologs exist for all the components. The 
most important DNA damage sensors belong to the phosphatidylinositol 3-kinase-like protein 
kinase (PIKKs) family (ataxia-telangiectasia mutated kinase (ATM), ataxia telangiectasia and 
Rad3-related protein (ATR) and DNA protein kinases, (DNA-PKc) and to the poly(ADP)
ribose polymerase (PARP) family. ATM and DNA-PK are activated in presence of DSBs2,10 
and  they mediate the HR and the NHEJ, respectively. ATR, in complex with its regulatory 
subunit ATRIP11, is recruited by the ssDNA-RPA complex in case of DNA polymerase stall 
therefore acting during SSB events. The PARP family has sixteen members but only PARP1 
and PARP2 are involved in the DDR12. The role of the DNA damage sensors is the recruitment 
of the mediator proteins to activate a signaling cascade. Mediators can act as substrates, as 
recruiters of other substrates or as scaffolds to allow the formation of complexes for the repair 
at the damage site, where the phosphorylation of the histone variant H2AX on the serine 139 
by ATM, ATR or DNA-PK13 occurs. Phosphorylation of H2AX plays a key role in DDR and is 
required for the assembly of DNA repair proteins at the sites containing damaged chromatin 
and for activation of checkpoints proteins, which arrest the cell cycle progression14. Mediator 
proteins, such as MDC1, and BRCA1 for ATM, TopBP1 (topoisomerase-binding protein1) and 
Claspin for ATR can activate the effector kinases. Finally, the effectors execute the functions of 
the DDR allowing the direct control of DNA repair, genomic stability and cell cycle regulation. 
Introduction 
41.1.2 Targeting DDR in cancer for drug development
 Treatment of cancer by radiotherapy or by chemotherapy causes significant collateral 
damages to normal tissues as well as side effects. The inhibition of the DDR in patients with 
cancer, lacking specific DDR functions could be a key strategy for target therapy. This concept 
is based on discoveries that show that the response to the damage is different depending on the 
cell cycle status (Figure 1.2). For example, cells in G1 (Gap 1 phase), lacking sister chromatid 
DNA, can repair DSB just through NHEJ pathway. Furthermore, there are also differences in the 
roles of the checkpoint at different stages of the cell cycle and in the DDR factors involved. For 
example, G1/S (synthesis phase) checkpoint allows time to repair DNA damage before starting 
DNA replication to avoid issues to DNA synthesis. The most important DDR factors involved 
are ATM, CHK2 and p53. The S phase checkpoint delays DNA replication to allow time to deal 
with unrepaired DNA damage or DNA damage resulting from collapsed replication forks. The 
DDR factors involved in this step are: ATR, CHK1, DNA PK and WEE1 (Wee1-like protein 
kinase). Finally, the G2 (Gap 2 phase)/M (mitosis) checkpoint allows to repair any remaining 
DNA DSBs before attempting cell division. In this step, DDR proteins such as CHK1, WEE1 
and MYT (Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase) are 
recruited. The G2/M checkpoint represents the last opportunity for the cell to prevent DNA 
damage before starting the mitosis stage15.
Introduction 
The latter ones include several proteins such as substrates of the CHK and PIK kinases, protein 
involved in DNA replication (i.e. MCMs, ORCs, RFC), transcription regulation and cell cycle 
control (i.e. p53, Cdc25, Nbs1 and BRCA1).
5Figure 1.2: DDR cell cycle targets. (Taken from O’Connor et al.9).
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 Three important key differences in cancer DDR provide a rationale for drug targeting 
(Figure 1.3).  
One relevant difference between normal and cancer cells is that most cancers have lost one or 
more DDR pathways. DDR deficiency results in a dependency on a particular DDR pathway or 
target for its survival. Thus, identifying a specific inhibitor for that target or relevant pathway 
is possible to specifically target the tumor cells. This approach is well known as synthetic 
lethality16,17.  The proof of this theory is given by the regulatory approval of olaparib (Lynparza), 
the first PARP inhibitor on the market18. Olaparib was initially approved in cancer treatments 
(i.e. breast and ovarian cancer) in the presence of mutated BRCA1 or BRCA2 genes, which 
leads to increase in genomic instability as well as increased susceptibility to the treatment with 
PARP inhibitors. 
Another important aspect, proper of cancer cells, is the replication stress. It occurs when the 
DNA polymerase is uncoupled from the replisome helicase activity19, generating extended 
6Introduction 
ssDNA at the replication fork. After the recognition of ssDNA by RPA (replication protein A) a 
DDR mediated by ATR20 is induced. Insufficiency in nucleotide pools can induce a replicative 
stress too. In cancer cells the deficiency in pRB (retinoblastoma protein), the amplification 
of cyclin D1 or cyclin E21 or the deletion of CDK2NA locus22, lead to the loss of the G1/S 
checkpoint. Thus, cells prematurely entry into S phase and DNA replication can start without 
all the necessary components, causing several issues, especially in the early S phase23. Cyclin 
E or MYC amplification and KRAS mutations increase the DNA replication initiation causing 
a conflict between the replication and transcription processes24-26. MYC overexpression leads 
also to the production of ROS species (reactive oxygen species) promoting the formation of 
damaged nucleotide as the 8 oxoguanine27. Replication stress, generated by chemotherapy, can 
therefore act more in cancer than in normal cells9. Currently, inhibitors of ATR (AZD6738 and 
VX970) and of its effector kinase CHK1 (GDC0575, LY2606368 and MK8776) are investigated 
in clinical trials9. However, it has been discovered that there is also a backup pathway involving 
DNA PK and CHK1 that can stabilize and repair the replication fork, therefore cancer cells can 
survey to the treatment with ATR inhibitors. 
The third approach to target cancer cells is increasing the level of endogenous DNA damage, 
which is achieved through radiotherapy and systemic chemotherapy. Even though there have 
been improvements to reduce the exposure of normal tissue to radiation, acute and chronic normal 
tissue toxicities represent a limiting factor for radiation dose delivery. A strategy to improve the 
specificity is combining the radiotherapy with the administration of DDR inhibitors. Several 
examples of DDR targeting agents combined with radiotherapy in preclinical and clinical trials 
have already obtained satisfactory results28,29. However, even though this approach represents 
a good starting point, many aspects are unknown, for example the dose of DDR inhibitors that 
7Introduction 
act as radiosensitizer and how much benefit is obtained from an extended exposure to the DDR 
agent following the irradiation. The main issues related to this strategy are the systemic delivery 
of chemotherapies and some overlapping side effects of DDR agents (i.e. gastrointestinal and 
bone marrow toxicity). In spite of these issues, preclinical and clinical studies have shown that 
chemo-resistant cancers can be sensitized through combination with DNA damaging agents17,30, 
therefore demonstrating the efficacy of combined therapies.
Figure 1.3: Major differences between normal and DDR cancer cells that can provide different strategies 
for drug targeting. (Taken from O’ Connor et al.9).
81. 2 Double strand breaks
 Among the several DNA lesions, DSBs are highly toxic since they can lead to 
aneuploidy, genetic aberration or cell death. As previously mentioned, DSBs can be generated 
by different sources, including treatment with genotoxic chemicals and ionizing radiation, 
collapsed replication forks and other endogenous DNA breaks. DSB repair uses three strategies: 
a homology-dependent error free HR, a potentially error prone KU dependent classical non 
homologous end-joining (C-NHEJ) and an error prone alternative non homologous end-joining 
pathway (A-NHEJ). The choice of one of these pathways depends on the phase of the cell cycle 
and on the DNA end resection31 (Figure 1.4).
Figure 1.4: Choice between Homologous Recombination and Non Homologous 
end Joining pathway for DSB repair. HR predominantly occurs in S and G2 phases; 
NHEJ is active throughout the cell cycle, playing a major role during G1 and M 
phases (Taken from Srivastava et al.32).
Introduction 
91.2.1 Classical non homologous end joining (C-NHEJ)
 C-NHEJ occurs throughout the cell cycle but especially during G1 and M33 (Figure 
1.5). The KU protein (heterodimer KU70-KU80 in eukaryotes) initially recognizes and binds 
the DSB in a sequence independent manner. The KU-DNA complex interacts with DNA PK 
forming a functional basket shaped structure, which encircles a molecule of dsDNA34. The 
asymmetrical ring allows the KU70 subunit to bind the major groove proximal to the DSB and 
the KU80 subunit the minor groove distal to the break site35 respectively, preventing the end 
access. The activation of the DNA-PK complex protein with its auto-phosphorylation induces 
both the opening of the central DNA-binding cavity and its release from the DNA ends. The 
following step is the DNA end processing, which depends on the nature of the damage and one 
or more enzyme activities can be involved. Indeed, in case of abasic or 5’-dRP/AP sites, the end 
processing occurs through the KU protein lyase activity; the tyrosyl DNA phosphodiesterase 
activity of TDP2 hydrolyzes 5’ phosphotyrosyl-DNA bonds and the polynucleotide kinase/
phosphatase (PNKP) generates 5’ phosphates and 3’ hydroxyl ligable ends. The recruitment 
of these enzymes depends on their interaction with the KU protein36. Finally, DNA ligase IV, 
together with XRCC4 and XLF (XRCC4 like factor), ties the processed ends.
Figure 1.5: Schematic representation of NHEJ repair pathway (Taken  from Srivastava et al.32).
Introduction 
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1.2.2 Alternative non homologous end joining (A-NHEJ)
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 A-NHEJ occurs especially when cells enter the S phase37. Many A-NHEJ events, also 
known as microhomology-mediated end-joining (MMEJ), require end resection and join the 
ends by base pairing at microhomology sequence, usually 5-25 nucleotides long, generating 
deletions at the junction. It has been shown that other A-NHEJ pathways do not require 
microhomology sequences. A-NHEJ shares similar step with C-NHEJ and the two pathways 
are competitive; in fact A-NHEJ occurs in the absence of the key C-NHEJ factors. Since 
KU limits poly ADP ribose synthesis, PARP1 tether DSBs under KU defective conditions38. 
PARP1 enzymatic activation leads to autoPARylation, resulting in decrease of PARP1 affinity 
for nucleosomes and subsequent relaxation of the chromatin. Importantly, PARP1 allows the 
recruitment of MRN complex, interacting with Mre11 and NBS1 proteins. In addition, it can 
promode the DNA end processing during the A-NHEJ beside its interaction with PNK, XRCC1 
and ligase IIIα39.
1.2.3 Homologous Recombination (HR)
 HR occurs during the S/G2 phases when sister chromatids are available as homologous 
templates40 (Figure 1.6). HR is fundamental in meiosis in which it allows the proper segregation 
of homologous chromosomes and it also favorites the generation of genetic diversity. As a key 
early step, the trimeric complex MRN and CtBP (C-terminal binding protein) interacting protein 
(CtIP) process the DNA ends. Further resection occurs by the 5’-3’ exonuclease activity of 
EXO1 or by the combined nuclease helicase activities of BLM/DNA2 (Bloom Syndrome RecQ 
Like Helicase/DNA replication helicase nuclease 2). The generated 3’ ssDNA tails are bound by 
RPA, which is subsequently replaced by RAD51 thanks to the help of several mediators, such 
as BRCA2 (breast cancer-associated 2) and RAD54. Once it is recruited RAD51 multimerizes 
forming nucleofilaments on ssDNA and several RAD51 paralogs, such as XRCC2, XRCC3, 
11
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Figure 1.6: Schematic representation of homologous recombination pathway. Depending on the second end 
capture, three independent pathways can operate: DSBR, SDSA and BIR. (Taken from Srivastava et al.32).
RAD51B, RAD51C and RAD51D act promoting or stabilizing RAD51 nucleofilaments. Then, 
RAD51 nucleoprotein filament searches for a homologous DNA sequence invading the intact 
dsDNA to form a heteroduplex DNA. Thus, a D-loop structure is generated in which RAD51 
also interacts with the dsDNA. The invading strand is then extended by DNA polymerase δ, 
PCNA and RFC41. The next step is the processing of the D loop, which can take place following 
different routes: the double strand break repair model (DSBR) and the synthesis-dependent 
strand annealing (SDSA). In the DBSR the second end of DSB is engaged to stabilize the D 
loop structure generating a double Holliday Junction (dHJ), which can be solved to produce 
crossover or non-crossover products or dissolved to exclusively generate non-crossover 
products. In the SDSA, the invading strand can be displaced from the D loop by DNA helicases 
followed by annealing with its complementary strand and DNA synthesis. SDSA mechanism 
preferentially occurs over DSBR during mitosis, instead DSBR is dominant throughout the 
meiosis in order to produce crossover products. Beyond HR, there are two more pathways to 
repair DSBs in a RAD51 independent fashion: NHEJ described above and the SSA (single 
strand annealing) pathway in which ssDNA sequences, formed during DSB processing, contain 
regions of homology at both sides of DSB that can be annealed and ligated42.
12
 RAD51, via interaction with BRCA2, plays a key role in HR and thus in the DSBs 
repair. The overexpression of RAD51 has been reported in several cancers, including breast, 
bladder, prostate, glioblastoma, lung and leukemia. RAD51 overexpression causes high levels 
of HR events, leading to genomic instability43. It has also been known that germline mutations 
of BRCA2 gene lead to an increased susceptibility to breast, ovarian and other cancer types. 
The inactivation of the HR pathway affects the survival of cells leading to a 300 fold increased 
sensitivity to anticancer drugs. For example, primary ovarian cancers are often responsive 
to cisplatin treatment, which has been correlated to decreased level of HR proteins, such as 
BRCA1 and FANCF, or mutations in BRCA1 and BRCA2. Furthermore, platinum-based 
therapy resistance in ovarian cancer cells is related to the re-expression of FANCF or genetic 
reversion of BRCA1 or BRCA2 mutations. These correlations emphasize the role of the HR 
pathway not only in response to the therapy, but also as a resistance mechanism. In this context, 
many lines of evidence indicate that the RAD51-BRAC2 complex, which is critical for cellular 
survival, constitutes a crucial element in tumorigenesis and its disruption provides an important 
target in anticancer therapies and as a chemosensitizer. 
 RAD51 is a highly conserved 339 amino acids recombinase enzyme involved in the 
essential steps of HR. RAD51 gene expression depends on several transcriptional activators and 
repressors44, but it is not affected by DNA damage45,46. RAD51 protein, as well as its homologous 
RadA and RecA proteins, is mainly present in homo-oligomeric form in the cytosol in normal 
cycling cells. This suggests that the level of nuclear RAD51 is due to regulated changes in its 
subcellular distribution and the nuclear availability of RAD51 must be regulated to enable 
appropriate levels of recombination. The N terminal domain structure of RAD51 is highly 
conserved from prokaryotic to eukaryotic organisms: it comprises five α-helices, a β strand 
1.3 RAD51-BRCA2: a key interaction for a successful DSB repair
Introduction 
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useful for protomer-protomer interactions and a typical α/β ATPase domain with nucleotide 
binding Walker motifs. Since RAD51 misses a nuclear localization signal (NLS) sequence, it 
has to be transported into the nucleus by the interaction with other proteins. This role is mainly 
played by the BRCA2 protein47, even though there are some evidences which show that the 
nuclear transport can also occur in a BRCA2 independent way, in particular with the help of 
RAD51 paralog, RAD51C48.  
 BRCA2, a 3418 amino acids protein, interacts with RAD51 through its eight repeats 
constituted by 35-40 amino acids (BRC repeats). BRC repeats are well conserved in different 
species and mutations in some of them confer sensitivity to DNA damage, suggesting their 
critical role for BRCA2 function. Among the eight BRCA2 motifs, BRC3 and BRC4 show the 
highest affinity for RAD51, instead BRC5 and BRC6 are inefficient RAD51 binders49,50. 
 The only published X-ray structure of a RAD51-BRC4 complex (Figure 1.7; PDB: 
1N0W) shows the most prominent points of contact characterizing the interaction between the 
two proteins. The crystal structure was obtained by removing the first 97 amino acidic residues 
of RAD51 and the two proteins, RAD51 and BRC4, were purified as a fusion protein linked by 
a flexible peptide51 ((Thr-Gly-Ser)4-Met-Gly).
Figure 1.7: Structure of RAD51 (C terminal region; blue) in complex with BRC4 
peptide (yellow). (Taken from Pellegrini et al.51). 
14
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a b
Figure 1.8: Hydrophobic interaction at RAD51-BRC4 interface (a) apolar interactions between the α helix of 
BRC4 (brown) and RAD51 surface (green); (b) hydrophobic interaction between the β hairpin of BRC4 and 
RAD51 surface. (Taken from Pellegrini et al.51).
The binding of BRC4 to RAD51 covers the core parallel β-sheet structure of RAD51 with 
two short antiparallel strands and an amphipathic α-helix (amino acids 1536-1542), which lies 
against the RAD51 exterior. This continuous contact between BRC4 and RAD51 is brought 
about by a 28 amino acid (1521-1548) segment of BRC4, which includes hydrophobic contacts 
as well as a number of charge-charge interactions along the interface. Two BRC4 sequences are 
essential for the interaction with RAD51 protein: 1524-FX1X2A-1527 and the sequence at the C 
terminal 1545-LFDE-1548. Phe1524 is located on the β strand hairpin and its aromatic ring is 
located in a RAD51 hydrophobic pocket formed by the side chains of residues Met158, Ile160, 
Ala190, Ala192, Leu203, Ala202 and Met210 (Figure 1.8a). Ala1527, in the second position of 
the hairpin loop, inserts its β carbon into a small pocket formed by the side chains of RAD51 
residues Phe166, Pro168, Leu171, Leu186 and Val189 (Figure 1.8b).
15
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The FX1X2A sequence acts mimicking the structure of an adjacent RAD51 monomer, thus 
it inhibits RAD51 assembly blocking oligomerization. The mimicked RAD51 sequence 
85-GGFTTATE-91 is highly conserved and it is located in the linker between the N terminal 
region and the catalytic core of the protein (Figure 1.9). The mutant forms RAD51 F86E and 
RAD51 A89E in vitro lose the ability to produce RAD51 filament, although they are still able 
to bind BRC4.
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Figure 1.9: Alignment of evolutionary conserved RAD51 sequences. Asterisks indicate two critical hydrophobic 
amino acid residues. (Taken from Pellegrini et al.51).
The amino acidic sequence 1545-LFDE-1548 of BRC4 is highly conserved in diverse organisms. 
In particular, the motif LF is mainly present in all eight human repeats as two hydrophobic 
residues. Phe1545 and Phe1546 provide hydrophobic interactions with a pocket between 
RAD51 helices A4 and A5, instead the glutamic acid forms a salt bridge with RAD51 Arg250. 
The interaction is enhanced by other hydrophobic contacts, such as Ile1534 in the linker region 
and Leu1539 and Val1542 in the α helix (Figure 1.8b). Beyond the hydrophobic interaction, 
polar and charged bindings occur between RAD51 and BRC4 (Figure 1.10). Asp187 of RAD51 
accepts a hydrogen bond from Ser1528 and electrostatically interacts with Lys1530. Finally, 
16
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Figure 1.10: Polar interaction between RAD51 (ribbon) and BRC4 (purple 
tubes). (Taken from Pellegrini et al.51).
Glu213 of RAD51 receives a hydrogen bond from Ser1538 of BRC4. It has been reported that 
mutations of relevant contact points of the RAD51-BRC4 interface affect the formation of the 
complex.
It has also been predicted that physiological modifications can decrease RAD51 affinity 
destabilizing the structure of BRC4. For instance, phosphorylation of Tyr1526 or Ser1538 
of BRC4 abolish the polar contact with Asp187 and Glu213 of RAD51, respectively52. The 
determination of the atomic structure of the BRC4 repeat in complex with the catalytic core of 
RAD51 allowed expanding the knowledge of the protein-protein binding and identifying the 
key residues of the interaction. However, the molecular description of the system is limited 
to static snapshots of the crystal structure and it is not sufficient to coherently describe the 
molecular processes occurring upon binding. 
 A mechanism explaining how BRCA2 modulates the DNA binding selectivity of RAD51 
and drives RAD51 filament formation has been recently proposed53,54. Beyond the BRC repeats, 
BRCA2 possesses at the C terminal, a second essential region for HR pathway modulation 
(Figure 1.11). 
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Figure 1.11: Functional domains in human BRCA2.  (Taken from San Filippo et al.55).
BRCA2 contains a DNA Binding Domain (DBD), characterized by a α helix followed by 
three OB folds, able to bind both ssDNA and dsDNA. BRCA2 is predominantly present in 
a dimeric form able to bind both ssDNA and RAD51 without dissociation. BRCA2 dimers 
offer mechanistic advantages because they impose the correct orientation to ssDNA and they 
can recruit two sets of RAD51 molecules arranged in opposite directions, one of which will 
be productive in ssDNA binding. The DBD binds weakly 12-20 nucleotides of ssDNA and 
tightly a sequence of 36 nucleotides of ssDNA , resembling the RPA DBD56. In this context, 
irrespective of its relative polarity, ssDNA can bind two of four DNA binding domains in one 
BRCA2 monomer and the other two different domains in the other BRCA2 monomer, allowing 
the correct orientation of ssDNA in both (Figure 1.12).
Figure 1.12: Structure of dimeric BRCA2 (pink) impose the correct polarity to ssDNA (black) by its DNA binding 
domains (1-4). ssDNA could simultaneously bind to domains 3 and 4 (OB2 and OB3) at the 5′ end (left side) of one 
BRCA2 monomer and domains 1 and 2 (α-helical domain and OB1) at the 3′ end (right side) of the second monomer. 
Dimeric BRCA2 recruits two sets of RAD51 molecules (orange) in opposing direction. (Taken from Shahid et al.54).
18
Introduction 
Recombination is initiated at the 3’ ssDNA tails generated by DSB resection. These tails enable 
multiple BRCA2 mediated nucleation events to originate a RAD51 nucleofilament in the 3’-5’ 
direction.  The unidirectional growth of the nucleofilament is most likely due to the presence 
of BRCA2 at 3’ end blocking dissociation, while allowing RAD51 self-polymerization at the 
other end (Figure 1.13).
Figure 1.13: Predicted model for nucleoprotein filament formation and elongation 
mediated by BRCA2. (Taken from Shahid et al.54).
Besides the formation of RAD51 nucleofilament assembly, BRCA2 regulates the DNA binding 
selectivity of RAD51. It has been shown that BRC domains can apparently have two opposing 
effects: they can block assembly of RAD51 nucleofilament on dsDNA and stabilize the 
nucleofilament47,57 itself, reflecting a complexity in the mechanism by which BRCA2 regulates 
RAD51. It has been observed that the stabilization of the nucleofilament on ssDNA by the 
single BRC4 repeat requires ATP hydrolysis. BRC4 acts preventing the dissociation of the 
ADP-RAD51 from the ssDNA, enabling the exchange of ADP with ATP within the filament 
and blocking ATP hydrolysis. The result is the formation and preservation of active ATP-
RAD51-ssDNA nucleofilament, which is the form required for DNA pairing function. Thus, 
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BRC4 acts in two ways: it enhances the pairing activity of RAD51 by slowing ATP hydrolysis 
meanwhile preventing the assembly of dsDNA-RAD51 filaments through impairment of 
RAD51 nucleofilament formation on dsDNA.  
 Recently, the different conformations of human RAD51-DNA complex, in the 
presynaptic and postsynaptic complexes, have been structurally described. The structures show 
as RAD51 protomers form a helical assembly via three interfaces58. The first one is mediated 
by an ATP molecule located between two adjacent protomers. In particular, the Walker motif 
A stabilizes the AMP-PNP (Adenylyl-imidodiphosphate) molecules with conserved residues 
K133 and T134. The second interface involves the packing of a short β strand of the linker 
region against the central β sheet of the ATPase domain in the adjacent protomer. Finally, the 
third interface corresponds to an aromatic packing between Tyr54 in the N terminal region of 
one protomer with F195 in the ATPase domain of the adjacent protomer. The ATP mediated 
interface represents the responsible for the correct presynaptic and postsynaptic complexes 
assembly, while the other two interfaces lead to the assembly stabilization. In the presynaptic 
complex three consecutive protomers hold a nucleotide triplet by the interaction of RAD51 
protomers residues with the phosphate backbone of the DNA (Figure 1.14a). These interactions 
promote the stretching of ssDNA to 1.5 times the length of B-DNA. In the postsynaptic 
complex, RAD51 forms mainly identical interactions with the invading strand. In particular, the 
presence of different RAD51-DNA configurations, which depend on the length of the micro-
homology region, has been predicted. Indeed, a micro-homology sequence of eight nucleotides 
corresponds to the threshold for a successful pairing event between two homologous DNA 
regions. In this context, Arg235 plays a critical role in the stabilization of the complementary 
strands in the stretched conformation: under a range of eight nucleotides the DNA joint is labile 
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because no more than two Arg235 are engaged, instead, micro-homology regions over eight 
nucleotides allow to reach the extension ratio up to 1.67 involving four RAD51 protomers in 
which three Arg235 residues stabilize the nascent DNA joint (Figure 1.14b).  
Figure 1.14: Model of RAD51-mediated DNA-strand exchange (a) RAD51 interacts with three DNA strands 
in the intermediate state. (b) Different RAD51-DNA configurations can exist, resulting in different lengths of 
DNA compared with B form DNA. (Taken from Xu et al.58).
a b
Even though these recent studies have allowed a partial understanding of the DNA recombination 
process mediated by RAD51, the molecular mechanism that takes place starting with the 
recruitment and transportation of RAD51 into the nucleus until its release at the end of the 
process, has not been completely described yet.
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1.4 Double strand break repair pathway: a target for cancer therapy
 Impairing the DSB repair mechanism administrating drugs that either interfere with 
protein-protein interactions or inhibit enzyme activities both represent an approach for 
sensitizing cancer cells to chemo- and radio-therapy. The HR and NHEJ pathways are not 
mutually exclusive, so one route cannot substitute the other one. As already mentioned, germline 
mutations in BRCA1 and BRCA2 are responsible for the hereditary susceptibility to breast 
and ovarian cancers.  Homologous deletion of the ATR gene is lethal for embryos as well as 
knockouts of the MRN complex59,60. Conversely, ATM knockout mice are viable although they 
show growth defects and a higher incidence of cancer61,62. 
 Knockout of RAD51 leads to embryos lethality, whereas RAD51 paralogs knockout 
exhibit nearly normal phenotype63. Furthermore, inhibition of either Ligase IV or XRCC4 
determines embryonic lethality, instead loss of Artemis or DNA-PKcs results viable, although 
they are associated with severe combined immunodeficiency (SCID)64. Defects in NHEJ and 
HR proteins can predispose the cells to cancer. In particular, mutations in DSB repair pathways 
can determine genomic instability and higher mutation rates, which may provide an advantage 
to cancer cells. Polymorphisms, upregulation or hyperactivation of DSB repair also support 
tumorigenesis (Figure 1.15).
Figure 1.15: HR and NHEJ proteins defects in various cancers. (Taken from Srivastava et al.32).
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 Inhibitors of HR are the most investigated DNA repair inhibitors. Mirin was the first 
identified inhibitor of the nuclease activity of the MRN complex65. It acts by killing BRCA2 
deficient cells, but since it has to be administrated in micromolar concentration, it can enhance 
the risk of undesired off-target effects acting upstream of NHEJ. Another strategy to impair HR 
is targeting the ATR-CHK1 and ATM-CHK2 pathways. KU-55933 represents the first selective 
inhibitor of ATM. It competes with the ATP binding site of ATM, inhibiting its catalytic activity66. 
VE-821 and NU6027 have been identified as ATR inhibitors and they are especially toxic in 
cell deficient in p53. VE-821 determines radio- and chemo-sensitization in pancreatic cells, 
whereas NU6027 is a pyrimidine analogue of adenosine triphosphate (ATP) molecule and it can 
act as a CDK inhibitor or it can confer cisplatin cytotoxicity independently of CDK inhibition. 
Small molecule inhibitors, ML216 for RecQ helicase BLM and NSC19630 for WRN have been 
identified. ML216 inhibits the DNA-dependent ATPase activity of BLM, but acts in a non-
competitive manner with respect to ATP. NSC 19630 affects DNA unwinding by interfering 
with the activity of WRN helicase and in combination with topotecan it acts synergistically to 
inhibit cell proliferation67.
 Among NHEJ proteins, many attempts have been made to target DNA PKcs. Wortmannin 
and LY294002 inhibit DNA PKcs and possess similar properties, indeed both sensitize cancer 
cells to IR treatment. Unfortunately, they show in vivo toxicity and off-target effects. NU7026 
and NU7441 are analogs of LY294002. Both have been reported to be very selective and 
potent DNA-PK inhibitors. However, their poor solubility and low bioavailability affect their 
administration in vivo. As far as KU proteins are concerned, no inhibitors have been published 
yet. 
Another strategy to impair the NHEJ pathway is targeting the final step of the process mediated 
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by Ligase IV. In this context, SCR7 inhibits NHEJ in vitro and in vivo and its mechanism of 
action is based on the accumulation of unrepaired DSBs. Importantly, it can potentiate the 
effects of chemo- and radio-therapy when coadministrated68. 
 Finally, many efforts have been conducted to validate inhibition of DNA end processing 
as a therapeutic target. Encouraging data support the possibility of impairing the activity of human 
polynucleotide kinase/phosphatase (hPNKP), the enzyme responsible for phosphorylation of 5’ 
hydroxyl termini and dephosphorylation of 3’ phosphate termini, which are often altered after 
IR treatment. Interestingly, the radiosensitation of breast and lung cells69 has been observed 
after treatment with this inhibitor.  
State of the art strategies for targeting RAD51 using small molecules
In addition to the role in DSB repair, RAD51 acts stabilizing the stalled replication DNA fork70,71 
to prevent nucleolytic degradation of nascent DNA. RAD51 overexpression in cancer cells 
enhances HR efficiency and leads to resistance after chemo- and radio-therapies treatments. 
RAD51 overexpression and the increase in foci formation could be due to the rapidly dividing 
cancer cells resulting in increased DNA replication stress. Interestingly, a major RAD51 
expression is not a consequence of gene amplification but it depends on increased gene 
transcription levels. In vivo studies have shown that RAD51 causes the formation of DNA-
RNA hybrid structures, which represent a danger for genome stability72. Furthermore, RAD51 
inhibition is correlated with a reduction of breast cancer migration suggesting that it can also 
contribute to metastases73. Taken together, these data show that beyond its canonical role as 
DNA repair protein, RAD51 can determine genotoxic effects and can be implicated in DNA 
damage and promotion of genomic alterations.
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 Recently, many efforts have been made to target RAD51 with small molecules as an 
anticancer therapy. Reduction of RAD51 expression levels helps to increase the sensitivity of 
cancer cells to the treatments with relatively smaller effects in noncancerous human cell lines74. 
Based on the knowledge of the processes in which RAD51 is involved, small molecules have 
been developed for targeting RAD51. It is possible to distinguish three classes of inhibitor 
compounds depending on their mechanism of action: compounds that inhibit RAD51-ssDNA 
filament formation, compounds that stimulate RAD51-ssDNA binding and compounds that 
inhibit RAD51 D-loop formation75. 
Compounds that inhibit RAD51-ssDNA nucleoprotein filament formation have been investigated 
with the purpose of affecting the capacity of RAD51 to bind ssDNA and consequently impairing 
both DSB repair and stalled replication forks. 4,4’-Diisothiocyanostilbene-2,2’-disulfonic acid 
(DIDS) was originally used as an inhibitor of membrane transporters and ionic channels, but 
it functions also as a RAD51-mediated D loop formation inhibitor with an IC50 of 1-10 μM. 
It acts by binding at or near the RAD51’s ssDNA binding site. However, further effects of 
DIDS were underestimated, in fact, it induces elevated cell toxicity. Another small compound, 
B02 interacts directly with RAD51 (Kd = 5.6 μM) preventing the formation of nucleoprotein 
filaments. B02 inhibits HR and increases cancer sensitivity to several DNA damaging agents, 
such as cisplatin, mytomicin C, doxorubicin and etoposide76. A similar effect has been observed 
using the compound Chicago Sky Blue (CSB, IC50 = 0.4 μM) and its analog compound RI-
1. Unfortunately, the chloromaleimide group of this class of compounds covalently binds 
the thiol group on the C319 residue of RAD51 leading to off-target effects. A SAR study has 
allowed discovering another analog, RI-2, which reversibly binds RAD51 but displays a six 
fold decrease in potency. 
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A different strategy is the stabilization of RAD51-ssDNA nucleofilaments by stimulating 
RAD51-ssDNA binding. RS-1 allows RAD51 to bind ssDNA tightly by locking RAD51 in the 
active conformation, therefore without affecting active site ATP hydrolysis. It has been shown 
that RS-1 acts mainly in malignant cells, which display increased RAD51 expression and its 
activity is dependent on RAD51 and RAD54B/RAD54L translocase77. 
Another class of RAD51 inhibitors acts by impairing the strand exchange activity of RAD51 
while keeping its ability to bind ssDNA. For instance, halenaquinone decreases the IR induced 
RAD51 foci and might act by blocking the formation of ternary complexes and rendering 
the presynaptic complex catalytically inactive78. Budke et al. successfully developed other 
compounds with similar effect, such as RI(dI)-1 and its analogs75. Among these class of 
compounds, RI(dI)-2 represents the best optimized RAD51 D-loop inhibitors. It sensitizes 
cancer cells to IR and can also inhibit SSA. 
1.4.1 Impairment of the double strand break repair pathway and synthetic lethality 
 Impairment of the DSB repair mechanism can also lead to sensitization of cancer 
cells to therapeutic DNA damaging agents. Actually, PARP inhibitors (PARPi) are currently 
administrated to women with germline mutations in the BRCA2 gene for treatment of breast 
and ovarian cancers. Indeed, these mutations make cancer cells more sensitive to PARPi. 
Most PARPi act trapping PARP1 at the site of damage, preventing both autoPARylation and 
PARP1 release from the DNA. The PARP1 catalytic cycle is therefore blocked with consequent 
DNA replication fork stalling. Thus, in BRCA-mutant tumors, in which the HR pathway is 
compromised, the administration of PARPi leads to cell death. Interestingly, the identification of 
PARPi for treatment of BRCA-mutant related cancers represents the first proof of principle study 
validating synthetic lethality as a cancer therapy (Figure 1.16). In 2014, olaparib (Lynparza™), 
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developed by AstraZeneca, became the first PARPi to be approved by FDA to treat advanced 
ovarian cancer associated with defective BRCA genes. Clinical trials are currently studying this 
drug to treat breast and pancreatic BRCA-mutant tumors. The synthetic lethality approach is 
based on the assumption that two genes are synthetically lethal, if loss or silencing of one of 
them is compatible with cell viability, while simultaneous loss of both genes leads to cell death. 
Synthetic lethality is here obtained by administering PARPi and simultaneously impairing the 
HR for DSB repair (BRCA2 mutation), therefore inhibiting cancer cells attempts to restore the 
therapeutic DNA damage induced.
Figure 1.16: Synthetic lethality. If genes essential for a repair pathway (i.e. gene 
A) are inactivated in normal cells, alternatives pathways (i.e. gene B) can function 
to respond to the DNA damage. Conversely cancer cells which already present 
mutations in genes essential for a DNA repair pathway cannot respond to the 
DNA damage if mutation or silencing occurs also in the alternative DDR pathway. 
(Taken from Huhn et al.79).
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The identification of a small molecule, able to disrupt RAD51-BRCA2 interaction, could in 
principle pharmacologically induce synthetic lethality by inhibiting the HR pathway in analogy 
with BRCA2 mutations. Inhibition of RAD51-BRCA2 interaction can be effective in treating 
patients without BRCA2 mutations and concurrently broaden the potential applications of 
PARPi in anticancer therapy. 
Few molecules have so far been described that are able to disrupt the RAD51-BRCA2 interaction. 
Among these small molecules, IBR2 has been reported to bind RAD51 and to inhibit in vitro 
and in vivo the interaction with BRCA2 (IC50 = 10 - 20 μM). Unfortunately, IBR2 suffers of 
significant stability and low bioactivity issues80. New studies for the identification of molecules 
able to prevent the RAD51-BRCA2 interaction are therefore necessary to overcome these 
IBR2 issues and exploit the inhibition of the RAD51-BRCA2 interaction as an effective tool to 
validate and boost up the synthetic lethality approach. 
Introduction 
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Goal of the research project
Goal of the research project
 Human RAD51 (hRAD51), via interaction with BRCA2, plays a key role in homologous 
recombination (HR) and thus in the repair of DNA double-strand breaks (DSBs). The 
overexpression of hRAD51 has been reported in a wide range of cancers including breast, bladder, 
glioblastoma, prostate, pancreas, lung and leukaemia81-84. hRAD51 has been also correlated with 
resistance to DNA damaging agents, such as temozolomide, and to radiotherapy43. In addition, 
hRAD51 down-regulation has been shown to increase cell chemo- or radio-sensitivity both in 
vitro and in vivo85.
 Oncology patients, carrying BRCA2 mutations, show enhanced sensitivity to some 
chemotherapeutic agents and radiotherapy86. Importantly, BRCA2-defective oncology patients 
show an increased susceptibility to poly ADP ribose polymerase inhibitors (PARPi), such as 
olaparib, which has been approved by FDA for treatment of BRCA-mutant tumors87. Olaparib 
acts by trapping PARP onto single-strand breaks, leading to the formation of DSB during the 
replication process (Figure 1.17). In tumors with HR deficiency due to BRCA1/2 mutations, 
this mechanism of action determines genomic instability and consequently cell death. This 
approach exploits the theory of synthetic lethality, which is a type of genetic interaction where 
the simultaneous occurrence of two genetic inactivations results in cellular death, but deletion 
of just one of them does not affect cell viability. In fact, targeting the synthetic lethal partner of 
a mutated gene can selectively kill cancer cells sparing normal cells.
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Figure 1.17: Mechanism of action of  olaparib in homologous recombination 
deficiency cancer cells (Taken from O’ Connor et al.9).
 Efficacy of PARPi is lost in tumors with active HR and resistance to the treatment with 
PARPi is often associated to an increased HR activity, due to either hRAD51 overexpression88 
or restoration of non-mutated BRCA289. Based on the above assumptions, our hypothesis is 
that disrupting hRAD51-BRCA2 interaction could affect the survival of cancer cells, making 
them sensitive to the treatment with PARPi. The long term aim of this research project is the 
identification of a small molecule, acting as an inhibitor of protein-protein hRAD51-BRCA2 
interaction, able to trigger a full synthetic lethality process in patients without BRCA2 mutations. 
This compound will be eventually administered to these individuals in combination with 
olaparib, mimicking the synthetic lethality induced by olaparib in BRCA2 defective oncology 
patients. The rationale of this approach lies on the evidence that spontaneous DNA alterations 
occurs more frequently in tumor cells rather than in normal cells because of their much higher 
genetic instability;  therefore, cancer cells heavily depend on DNA repair mechanisms. Normal 
cells, which experience much less DNA damage, may be affected by DNA repair inhibitors 
at much lesser extent relative to cancer cells. Simultaneous administration of olaparib with 
RAD51-BRCA2 inhibitors should preferentially affect cancer cells hence supporting our 
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approach from the selectivity standpoint.
 In this context, we propose a multidisciplinary project (Figure 1.18) to validate the 
protein-protein interaction hRAD51-BRCA2 as a target for anticancer drug discovery in 
combination therapies with PARPi. To achieve this aim, the first step is the identification of small 
molecules able to disrupt the hRAD51-BRCA2 interaction through a virtual screening campaign 
on the only available X-ray crystal structure of the hRAD51-BRC4 complex (PDB: 1N0W).
The identified compounds are synthetized and tested through biochemical and biophysical 
assays for their ability to interfere with hRAD51-BRC4 interaction. Their affinity (Kd) and 
kinetic (kon, koff) parameters for the binding to hRAD51 are also determined. In parallel, cell-
based experiments are carried out to investigate the anticancer activity of the novel compounds 
alone or in combination with PARPi. Pancreatic adenocarcinoma cells are used as the model 
for the cell-culture experiments because of its clinical relevance. For this tumor form, there is a 
well-studied cell line lacking functional BRCA2 (the Capan-1 cell line). The BRCA2-proficient 
cell lines for the study are BxPC3 and Panc-1. BxPC3 cells offer an appropriate comparison 
to Capan-1 because they match the Capan-1 line in terms of tumor type and differentiation 
state. The effects of the most promising inhibitors on BRCA2 deficient cell lines derived 
from human breast and ovarian cancers are also studied. The obtained results will contribute 
to the identification of hit and lead compounds, which will be further improved through the 
information gained from the X-ray crystal structure of hRAD51-inhibitors complex. Virtual 
screenings and the synthesis of the compounds are carried out in Italian Institute of Technology 
(IIT), while cell-based experiments are performed by our collaborators at the University of 
Bologna. Biochemical assays are carried out by our collaborators in Perugia. Support for 
structural sample preparation and data collection is provided by the National Center for Protein 
Goal of the research project
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Figure 1.18 : Overview of the research project.
Within this project, the goal of my PhD research activity is the characterization, through 
biophysical techniques, of the hRAD51-BRCA2 interaction and of the hRAD51-new inhibitor 
molecules interactions. My research work is critical to confirm the ability of the newly identified 
compounds to specifically target the protein-protein hRAD51-BRCA2 interaction, which is 
viable for cellular survival. Moreover, the biophysical characterizations provide strong support 
to the identification of new molecules able to interfere with the hRAD51-BRCA2 interaction. 
The aims of my PhD project are:
- Optimization of a protocol for the overexpression and purification of full-length hRAD51 
in bacteria cells;
- Biophysical characterization of hRAD51-hit molecules interaction through surface 
plasmon resonance (SPR), Nuclear Magnetic Resonance (NMR) spectroscopy and 
Microscale Thermophoresis (MST)
- X-ray structural characterization of hRAD51-BRCA2  
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2.1 Materials
Bacterial cultures were grown in the following media: Luria-Bertani (LB) medium, M9 medium, 
SOC medium, ZYM-5052 and Terrific Broth (TB)-5052 auto-induction media.
2.1.1 Growth media
Luria-Bertani medium 
LB medium is the most widely used broth for bacterial cells growth. Its composition is reported 
in the following Table 2.1:
Table 2.1: Composition of LB broth and LB agar.
LB medium and LB agar were sterilized in autoclave at 121 °C for 20 minutes.
M9 medium
M9 medium is defined as a minimal broth. In fact, it contains only salts and nitrogen, so it 
is generally supplemented with a carbon source (e.g. glucose), amino acids and vitamins as 
needed. The composition is reported in Table 2.2:
Table 2.2: Composition of M9 medium.
M9 medium sterilized in autoclave at 121 °C for 20 minutes was supplemented with sterilized 
solutions of glucose 0.4% (w/v), MgSO4 1 mM and CaCl2 3 mM.
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Super Optimal Catabolite repression (SOC) medium
SOC medium (Table 2.3) is defined as a rich bacterial growth medium that is used to maximize 
the transformation efficiency of E. coli in the final step of bacterial cell transformation.
Table 2.3: Composition of SOC-medium.
SOC medium was sterilized in autoclave at 121 °C for 20 minutes.
Auto-induction media
Auto-induction media, like ZYM-5052 and TB-5052 are very useful for protein production and 
usually result in significantly higher protein yields compared to conventional media. In strains 
such as BL21, the T7 RNA polymerase is under control of the lacUV5 promoter, inducible 
with lactose. The addition of glucose, glycerol and α-lactose (5052 solution) into the medium 
allows to obtain an auto-induction medium. In fact, bacteria use glucose as primarily source 
of carbon which, at the same time, prevents the activation of lac operon by lactose, promoting 
the catabolite repression. In this condition, the production of the heterologous protein is not 
allowed. Hence, exhaustion of the glycerol causes two effects: bacteria will use glycerol as 
carbohydrate source and lactose will be internalized into the cells to promote the activation of 
lac operon with consequent expression of the recombinant protein.
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ZYM-5052 medium
In ZYM-5052 auto-induction medium potassium and sodium phosphate avoid the pH drop of 
the medium (6.75 at 25 °C). In Table 2.4 the medium composition is reported:
Table 2.4: Composition of ZYM-5052 medium.
ZY and 5052 (50X) solutions, sterilized in autoclave at 121 °C for 20 minutes, were supplemented 
with sterilized M solution (Na2HPO4 25 mM, KH2PO4  25 mM, NH4Cl 50 mM, Na2SO4 5 mM) 
and MgSO4 2 mM to prepare the ZYM-5052 medium.
Terrific Broth-5052
Terrific Broth (TB) is an enriched medium, which helps the recombinant E. coli strains of 
maintaining an extended growth phase. The large amount of yeast and tryptone provides 
additional nutrients and growth factors required for enhanced growth of cells. The potassium 
phosphates are present to prevent a drop in the pH (7.2 ± 0.2 at 25 °C) of the medium during 
bacterial growth. The medium composition is reported in the following Table 2.5:
Table 2.5: Composition of TB-5052 medium.
TB and 5052 (50X) solutions were sterilized in autoclave at 121 °C for 20 minutes. TB-5052, 
obtained adding 20 mL of 5052 (50X) solution to 980 mL of TB, was supplemented with a 
sterilized solution of MgSO4 (2 mM final concentration).
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2.1.2 Solutions and reagents
SDS-PAGE sample loading buffer: 4X: 0.25 M Tris-HCl pH 6.8, 8% SDS, 0.3M DTT, 30% 
Glycerol, 0.02% Bromphenol blue;
MOPS SDS running buffer: 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 
7.7; (Invitrogen);
Staining solution: (40% EtOH, 10% acetic acid, 0.05% w/v comassie blue G-250);
Destaining solution: (25% ethanol, 8% acetic acid);
Transfer buffer: NuPAGE transfer buffer (Invitrogen);
TBS-T buffer: 137 mM NaCl, 2.7 mM KCl, 19 mM Tris base, 0.1% (v/v) Tween20;
Blocking solution: TBS-T buffer supplemented with 5% (w/v) milk;
DNA sample loading buffer: Gel Loading Dye, Blue (6X) (New England Biolabs);
Tris-Borate-EDTA (TBE) buffer: 89 mM TrisBase, 89 mM Boric acid, 2 mM EDTA;
Agarose gel: Tris-Borate-EDTA (TBE) buffer: 89 mM TrisBase, 89 mM Boric acid, 2 mM 
EDTA supplemented with (w/v) % agarose depending on the desired final gel concentration.
2.1.3 Peptide
BRC4: BRC4 peptide was purchased from Thermo Scientific, Invitrogen.
2.1.4 Antibodies
Anti-RAD51: polyclonal antibody produced in mouse, purified immunoglobulin (SIGMA-
ALDRICH);
Anti-Mouse + HRP: Rabbit Anti-Mouse IgG H&L (HRP) (Abcam).
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2.2 Molecular Biology
2.2.1 Plasmids for recombinant protein expression
pGEX-4T-1 plasmid (GE Healthcare) is designed for high-level intracellular expression of genes 
or gene fragments. Expression is inducible in E. coli by Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) addition. It allows to produce tagged proteins with a GST moiety at the amino terminus 
or at the carboxyl terminus (Figure 2.1). The gene coding for β-lactamase is present in the 
plasmid’s DNA sequence conferring ampicillin resistance to cells transformed with this plasmid.
 hRAD51 gene sequence was cloned between BamHI and SalI restrictions sites to 
produce a recombinant protein with a GST tag at the N terminal region.
pGEX-4T-1 plasmid
Figure 2.1: pGEX-4T-1 plasmid map. (Taken from https://www.addgene.
org/vector-database/2876/).
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pET15b plasmid (Novagen) is a medium copy number plasmid characterized by the presence 
of a T7 promoter for the expression of heterologous protein by induction with IPTG. pET15b 
carries a N-terminal His-tag sequence followed by a thrombin site and three cloning sites 
(Figure 2.2). The gene coding for β-lactamase present in the plasmid’s DNA sequence confers 
ampicillin resistance to cells transformed with this plasmid. 
 hRAD51 and hRAD51 F86E gene sequences were subcloned between BamHI and 
Bpu1102I restriction sites in order to overexpress the protein of interest with a hexahistidine 
moiety at the N terminal region.
pET15b plasmid
Figure 2.2: pET15b plasmid map. (Taken from:  https://www.
addgene.org/vector-database/2543/).
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pET28a plasmid (Novagen) is a medium copy number plasmid. The expression of recombinant 
protein, by IPTG induction, is regulated by the T7 promoter. pET28a carries an N terminal His-
Tag-thrombin-T7-Tag configuration plus a C terminal His-Tag sequence (Figure 2.3). Bacterial 
cells trasformed with this plasmid can be selected in media containing kanamycin. 
 Gene sequence coding for BRC4 peptide was subcloned between NcoI and SalI 
restriction sites in order to express the heterologous protein with a hexahistidine tag at the N 
terminal region.
pET28a plasmid 
Figure 2.3: pET28a plasmid map. (Taken from: https://www.
addgene.org/vector-database/2565/).
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E. coli BL21(DE3)pLysS (Promega) strains are lysogenic for λ-DE3 that contains the T7 
bacteriophage gene I, encoding T7 RNA polymerase under the control of the lac UV5 promoter. 
BL21(DE3)pLysS also contains a plasmid, pLysS, which carries the gene encoding T7 lysozyme. 
T7 lysozyme lowers the background expression level of the target genes under the control of the 
T7 promoter but does not interfere with the level of expression achievable after IPTG induction. 
The genotype is: F-, ompT, hsdSB (rB-, mB-), dcm, gal, λ(DE3), pLysS, Cmr.
2.2.2 Competent cells
BL21(DE3)pLysS cells
Rosetta2(DE3)pLysS cells
E. coli Rosetta™ 2 host strains (Novagen) are BL21 derivatives designed to enhance the 
expression of eukaryotic proteins that contain codons rarely used in E. coli. The main difference 
with BL21(DE)pLysS cells is due to the presence of tRNAs for 7 rare codones (AGA, AGG, 
AUA, CUA, GGA, CCC, and CGG) on a compatible chloramphenicol-resistant plasmid. The 
tRNA genes are driven by their native promoters. The genotype is: F- ompT hsdSB(rB- mB-) 
gal dcm (DE3) pLysSRARE2 (CamR).
XL1-Blue cells
E. coli XL1-Blue cells (Agilent Technologies) are endonuclease (endA) deficient cells, to 
improve the quality of mini-prep DNA, and are recombination (recA) deficient to promote insert 
stability. A hsdR mutation prevents the cleavage of cloned DNA by the EcoK endonuclease 
system. The lacIq Z∆M15 gene on the F´ episome allows blue-white color screening. The 
genotype is: recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F´ proAB lacIq Z∆M15 
Tn10 (Tetr)].
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2.2.3 XL1-Blue, BL21(DE3)pLysS and Rosetta2(DE3)pLysS cells transformation
2.2.4 Plasmid DNA purification
An aliquot of 50 μL of competent cells (XL1-Blue, BL21(DE3)pLysS and Rosetta2(DE3)
pLysS cells) were thawed on ice and transformed with about 25 ng of DNA plasmid. After 
plasmid DNA incubation for 30 minutes on ice, cells were subjected to heat shock at 42 °C for 
45 seconds and successively 2 minutes on ice. Afterwards, cells were grown in SOC medium at 
37 °C for 45 minutes under shaking (200 rpm) and then plated on agar plates supplemented with 
the appropriate antibiotic (ampicillin 100 μg/mL and/or kanamycin 50 μg/mL) for the selection 
of transformed cells.
A single colony of XL-1 Blue cells transformed with the plasmid of interest was grown at 37 
°C in an appropriate volume (10 mL for mini-prep or 150 mL for maxi-prep) of LB medium 
supplemented with the appropriate antibiotic.  The saturated bacterial cultures were centrifuged 
at 6000 rpm for 10 minutes. Afterwards, plasmid DNA purification was carried out using 
QIAprep Spin Kit (Qiagen) and Plasmid Maxi Kit (Qiagen) for mini-prep and maxi-prep, 
respectively, following the manufacturer’s instructions.
2.2.5 hRAD51 subcloning into pET15b vector 
Two different primers, purchased from Metabion (Semmelweisstrasse, Germany) were designed 
in order to subclone the gene coding for hRAD51 into a pET15b vector:
- RAD51 BamHI Fw: 5’ CGTGGATCCGATGGCAATGCAGA 3’
- RAD51 Bpu1102I Rev: 5’ GCTCGGCTCAGCTCAGTCTTTG 3’
hRAD51 sequence was amplified by polymerase chain reaction (PCR). PCR reaction was 
carried out using the high fidelity Pfu polymerase for 33 cycles of 95 °C for 2 minutes → 95 °C 
for 30 seconds → 66 °C for 30 seconds → 68 °C for 30 seconds followed by 68 °C for 7 minutes 
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at 4 °C until electrophoresis. 
 The PCR product was purified through QIAquick PCR purification kit as described by 
manufacturer’s instructions. Afterwards, the PCR product and the pET15b plasmid were double 
digested by BamHI and Bpu1102I (NewEngland BioLabs) upon incubation at 37 °C for 1.5 h. 
The digested products were run in 1% agarose gel. Bands corresponding to double digested 
hRAD51 and pET15b plasmid were extracted from the gel and purified using QIAquick Gel 
Extraction Kit following manufacturer’s instructions. Finally, purified hRAD51 and pET15b 
DNA sequences were ligated by adding T4 DNA ligase (Invitrogen) and incubating for 25 
minutes and room temperature. The new construct pET15b-His-hRAD51 was used to transform 
XL1-Blue cells through heat-shock method and then plated on agar plates containing ampicillin 
(100 μg/mL). After extraction of the plasmid using the QIAprep Spin Kit (Qiagen), the plasmid 
was sequenced. Plasmid with the correct sequence was transformed in Rosetta2(DE3)pLysS 
cells to express and produce the recombinant protein hRAD51 with a hexahistidine tail at the 
N-terminus.
2.2.6 Site-directed mutagenesis
Primers to introduce the F86E mutation in the vector pET15b-His-hRAD51 were purchased 
from Metabion (Semmelweisstrasse, Germany) The QuikChange II Site-Directed Mutagenesis 
kit (Agilent Technologies) using the polymerase chain reaction (PCR) was used to introduce 
the mutation. 
- Primer RAD51 F86E Fw 5’ CAGCTAAATTAGTTCCAATGGGTGAAACCACTGCAACTGAATTCC 3’
- Primer RAD51 F86E Rev 5’ GGAATTCAGTTGCAGTGGTTTCACCCATTGGAACTAATTTAGCTG 3’
Mutated plasmid was transformed in E. coli XL1-Blue competent cells through heat-shock 
method and then plated on agar plates containing ampicillin (100 μg/mL). After extraction of 
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the plasmid using the QIAprep Spin Kit (Qiagen), the plasmid was sequenced. Plasmid with 
the correct mutation were transformed in Rosetta2(DE3)pLysS cells to express and produce the 
recombinant protein hRAD51 F86E with a hexahistidine tail at the N-terminus.
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2.3 Biochemical methods
Agarose gel electrophoresis promotes the separation of biomolecules, such as nucleic acids 
or protein, in an agarose matrix applying an electric field. Agarose gel electrophoresis was 
performed using 1% (w/v) agarose gel prepared as described in section 2.1.2. 
Before loading DNA samples into the wells, an appropriate volume of gel loading dye was 
added to the samples. The running of DNA samples was carried out applying a constant voltage 
of 120 V for 50 minutes using the horizontal electrophoresis apparatus (Mini-Sub® Cell GT 
Systems; Biorad) in TBE buffer supplemented with SYBR Safe DNA Gel Stain (Invitrogen).
2.3.1 Agarose gel electrophoresis
SDS-PAGE promotes the separation on polyacrylamide gels in the presence of SDS of proteins 
according to their molecular weights applying an electric field. SDS-PAGE was performed 
using precast polyacrylamide gels (NuPAGE 4-12% BisTris-Gel, Invitrogen) run in XCell 
SureLock™ Mini-Cell Electrophoresis System (Invitrogen).
Cell lysates or protein samples, after addition of an appropriate volume of loading sample 
buffer, were denatured by boiling them for 5 minutes at 95 °C. Samples were loaded into the 
wells; the running was performed with a constant voltage of 120 V for about 90 minutes in 
MOPS SDS running buffer.
The gels were then incubated in a staining solution for 1 h at room temperature. Finally, gels 
were destained using a destaining solution.
2.3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
Protein bands were excised from the polyacrylamide gel and cut in small cubes (1 mm). Gel 
particles were covered with acetonitrile and then rehydrated in 0.1 M NH4HCO3. After 5 minutes 
2.3.3 In-gel digestion of proteins separated by polyacrylamide gel electrophoresis
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of incubation, an equal volume of acetonitrile was added to wash gel pieces. The liquid was 
removed after 15 minutes and the gel particles were dried in a SpeedVac System. Gel pieces 
were swelled in 10 mM DTT/0.1 M NH4HCO3 and incubated for 45 minutes at 56 °C to induce 
proteins reduction. The excess liquid was removed and the gel particles were shrunk with 
acetonitrile that was quickly replaced with 55 mM iodoacetamide in 0.1 M NH4HCO3. Gel 
pieces were incubated in this solution for 30 minutes in the dark. The liquid was removed and 
the gel particles were washed with 0.1 M NH4HCO3 and acetonitrile as described above. Gel 
pieces were completely dried in a SpeedVac system and then rehydrated with a digestion buffer 
(50 mM NH4HCO3, 5 mM CaCl2, trypsin 12.5 ng/μL (Boehring Mannheim sequencing grade) 
at 4 °C. After 120 minutes 40 μL of digestion buffer without trypsin was added to the mixture 
to keep gel pieces hydrated during enzymatic cleavage overnight at 37 °C. The peptides were 
recovered from the gel by addition of a volume of 25 mM NH4HCO3 sufficient to cover the gel 
pieces. After incubation for 15 minutes, the same volume of acetonitrile was added. After other 
15 minutes incubation, the supernatant was recovered. The extraction was repeated two times 
with 5% formic acid. All the extracts were pooled and completely dried in the SpeedVac System 
before HPLC-MS analysis.
2.3.4 Western Blot
SDS-PAGE gels were run as described in section 2.3.2. Protein separated by SDS-PAGE were 
blotted onto nitrocellulose membranes (Protran BA83 Nitrocellulose Blotting Membrane, 0.2 
µm, 20 × 20 cm; Ge Healthcare) applying a constant voltage of 25 V for 2 hours in transfer 
buffer. 
After blotting the proteins on membranes, they were blocked for at least 2 h using the blocking 
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solution. Subsequently, the membranes were incubated overnight at 4 °C with the primary 
polyclonal antibody against hRAD51 (1:1000 dilution in blocking solution). The day after, the 
membranes were subjected to three washes using TBS-T buffer and then incubated with the 
secondary antibody for 1 h at room temperature (1:10000 dilution in blocking solution). Finally, 
the membranes were washed three times in TBS-T solution. The membranes were exposed to 
the LiteAblot Extend Chemiluminescent Substrate (EuroClone) for a period sufficient to detect 
the bands and an image was recorded using the LAS4000 (Fujifilm) instrument.
Protease inhibition trials
In order to inhibit the GST-hRAD51 proteolytic degradation by ClpX protease and HslV-HslU 
protease complex different parameters were modified: addition to the bacteria growth medium 
of 1 mM ZnSO4 or 300 mM KCl, alone or in combination, the bacteria growth media (M9, LB, 
ZYM-5052), the temperature of bacteria growth and induction (20 °C or 37 °C) and the time of 
induction (2 h, 3 h, 4 h or overnight for LB medium; 2 h and overnight for M9 medium; 16 h, 
20 h and 24 h for ZYM-5052 medium). 
Protease inhibition trials were performed starting from a pre-culture of BL21(DE3)pLysS/
pGEX-4T-1-GST-hRAD51 cells grown overnight in LB medium at 37 °C. The saturated 
overnight culture was added to fresh LB supplemented with or without ZnSO4 or KCl alone or 
in combination, or to the media cultures mentioned above starting from an initial OD600 of 0.1 - 
0.2. For growth and induction in LB or M9 media, flasks were incubated at 200 rpm and 37 °C 
until cells reached OD600 of 0.6 - 0.7. Then, IPTG was added at 0.5 mM final concentration and 
induction was performed overnight at 37 °C or 20 °C. 
2.3.5 Recombinant GST-hRAD51: expression, purification and protease inhibition trials
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For auto-induction medium ZYM-5052, flasks were incubated shaking at 200 rpm and 37 °C 
or 20 °C. 
Proteolytic degradation was tested through western blot analysis on volumes of bacterial culture 
determined by Equation 2.1. Bacteria were centrifuged and all the pellets were resuspended in 
the same amount of sample loading buffer to obtain equal cells concentrations.
Equation 2.1
Protocol for expression and purification of GST-hRAD51
hRAD51 was expressed in E. coli BL21(DE3)pLysS cells. A saturated overnight culture of 
BL21(2DE3)pLysS/pGEX-4T-1-GST-hRAD51 was added into a fresh LB medium containing 
ampicillin to reach an initial OD600 of 0.1 - 0.2. Flaks were shaken at 200 rpm and 37 °C 
until the cells reached the mid-log phase (OD600 0.6 - 0.7). Then IPTG was added to a final 
concentration of 0.5 mM. The bacterial culture was induced at 37 °C for 4 h. Subsequently, cells 
were centrifuged for 10 minutes at 6000 rpm and 4 °C. The cell pellet was frozen at -80 °C. 
The bacteria cells pellet was subsequently resuspended in an appropriate volume of lysis buffer 
(100 mM Tris-HCl (pH 8.00), 7% (v/v) glycerol, 0.5 mM EDTA, 10% (w/v) Sucrose, 300 mM 
NaCl, 5 mM DTT, Urea 0.5 M) supplemented with protease inhibitor cocktail (SIGMAFAST™ 
Protease Inhibitor Cocktail Tablets, EDTA-Free). To the resuspended pellet PMSF 1 mM 
and lysozyme 100 μg/mL were added. The cell suspension was lysed on ice by sonication 
(12 rounds of 30”; Amplitude 85%; Tip KE76; Bandelin Sonoplus HD2070 sonicator). The 
disrupted cell suspension was centrifuged for 1 h at 13000 rpm. The supernatant fraction was 
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filtered with  a 0.45 μM membrane (MiniSart Syringe filter 0.45 μM) to remove residual particles 
before chromatography. The supernatant was applied onto a GST-Trap column (GSTrapTM FF 
1 mL; GE Healthcare) equilibrated with buffer A (50 mM Tris-HCl pH 8.00, 150 mM NaCl, 
1 mM DTT, 0.5 mM EDTA, 1 mM Deoxy-cholate) using an Akta purifierTM 10 system (GE 
Healthcare). The column wash washed with buffer A until a stable baseline was reached and 
then the bound fusion protein GST-hRAD51 was eluted with a linear gradient over 10 column 
volumes using buffer B (buffer A supplemented with 10 mM reduced glutathione). The peak 
fractions containing the fusion protein were pooled and subsequently concentrated using an 
Amicon ultra centrifugal filter (cutoff 30 kDa; EMD Millipore) up to 1 mL final volume.  
The pooled fractions were injected onto a gel filtration column (Superdex200 Increase 10/300 
GL, GE Healthcare) equilibrated with buffer C (20 mM Tris-HCl (pH 8.00), 5% (v/v) Glycerol, 
150 mM NaCl, 1 mM DTT, 1 mM Deoxy-cholate, 0.5 mM EDTA).
 GST-hRAD51 purity was checked by SDS-PAGE and stored at -80 °C for further 
analysis.
2.3.6  Recombinant His-hRAD51: expression, purification and degradation trials
E. coli Rosetta2(DE3)pLysS cells were transformed with pET15b-His-hRAD51. Different 
parameters were modified for the optimization of the His-hRAD51 expression protocol: 
the bacteria growth medium (LB medium, ZYM-5052 and TB-5052 auto-induction media), 
temperature of  E. coli growth (20 °C or 37 °C) and induction (20 °C or 37 °C), IPTG concentration 
(0.05 mM, 0.1 mM, 0.25 mM and 0.5 mM for growth in LB medium;) and time of induction 
(2 h, 3 h, 4, overnight for growth and induction in LB medium; 24 h, 32 h, 48 h, 56 h, 72 h for 
His-hRAD51 expression trials
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growth in auto-induction media). His-hRAD51 expression trials were performed starting from 
a pre-culture in Rosetta2(DE3)pLysS/pET15b cells grown overnight in LB medium at 37 °C. 
The saturated overnight culture was added to fresh LB or to the  auto-induction media to reach 
a starting OD600 of 0.1 - 0.2. For growth and induction in LB medium, flasks were incubated at 
200 rpm and 37 °C until cells reached OD600 0.6 - 0.7. Then, IPTG was added at 0.5 mM final 
concentration and induction was performed overnight at 37 °C or 20 °C. 
For growth in auto-induction media ZYM-5052 and TB-5052, flasks were incubated shaking at 
200 rpm and 20 °C. The optical density (OD600) of the bacterial cultures were measured at the 
end of the induction to characterize the bacteria growth under each condition. 
Proteolytic degradation of His-hRAD51 in Rosetta2(DE3)pLysS cells was evaluated by western 
blot loading the soluble fraction of proteins extracted from E. coli bacteria cells grown under 
different conditions as described above for GST-hRAD51.
Degradation trials of His-hRAD51
Protocol for the expression and purification of His-hRAD51
hRAD51 was expressed in E. coli Rosetta2(DE3)pLysS cells. A saturated overnight culture of 
Rosetta2(DE3)pLysS/pET15b-His-hRAD51 was diluted (1:1000) into a fresh TB-5052 auto-
induction medium containing ampicillin (100 μg/mL). The flasks were shaken at 200 rpm at 
20 °C for 72 h. Subsequently, cells were centrifuged for 10 minutes at 6000 rpm and 4 °C. Cell 
pellet was frozen at -80°C.
Pellet was subsequently resuspended in an appropriate volume of buffer A (20 mM Tris-HCl 
(pH 8.00), 500 mM NaCl, 10 mM Imidazole, 5 mM DTT, 10% (v/v) Glycerol) supplemented 
with protease inhibitor cocktail (SIGMAFAST™ Protease Inhibitor Cocktail Tablets, EDTA-
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Free). The cell suspension was lysed on ice trough sonication (24 rounds of 30”; Amplitude 
85%; Tip MS72; Bandelin Sonoplus HD2070 sonicator). The disrupted cell suspension was 
centrifuged for 1 h at 13000 rpm. The supernatant fraction was filtered with a 0.45 μM (MiniSart 
Syringe filter 0.45 μM) membrane to remove residual particulates before chromatography. 
The supernatant was applied onto a His-Trap column (His-TrapTM FF 5mL, GE Healthcare) 
equilibrated with buffer A.  A wash step was performed using 10% of buffer B (20 mM Tris-
HCl (pH8.00), 500 mM NaCl, 500 mM Imidazole, 10% (v/v) Glycerol). The protein was then 
eluted with a linear gradient from 10% to 100% of buffer B over 10 column volumes. Fractions 
(0.5 mL) were collected and analyzed by SDS-PAGE. Collected fractions corresponding to 
the recombinant protein were dialyzed overnight at 4 °C against buffer C (50 mM Tris-HCl 
(pH 8.00), 200 mM KCl, 0.25 mM EDTA, 2 mM DTT, 10% (v/v) glycerol). Dialyzed protein 
was loaded onto an anion exchange column (ResQ, GE Healthcare) equilibrated in buffer C. 
The elution was performed with a linear gradient of buffer B (50 mM Tris-HCl (pH 8.00), 1 
M KCl, 0.25 mM EDTA, 2 mM DTT, 10% (v/v) glycerol). Fractions (0.5 mL) were collected 
and analyzed by SDS-PAGE. Fractions containing His-hRAD51 were pooled and dialyzed 
against the storage buffer (20 mM Hepes (pH 8.00), 250 mM KCl, 0.1 mM EDTA, 2 mM DTT, 
10% (v/v) glycerol). The protein yield was determined from the optical absorption at 280 nm 
(extinction coefficient 14900 M-1cm-1) of the final sample. 
2.3.7 His-hRAD51-BRC4 complex: expression and purification
hRAD51-BRC4 complex was expressed in E. coli Rosetta2(DE3)pLysS cells. A saturated 
overnight culture in LB-medium of Rosetta2(DE3)pLysS co-transformed with pET15b-His-
Protocol for the expression and purification of His-RAD51-BRC4 complex
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hRAD51 and pET28a-BRC4 was diluted (1:1000) into a fresh TB-5052 auto-induction medium 
containing ampicillin (100 μg/mL) and kanamycin (50 μg/mL). The flasks were shaken at 200 
rpm at 20 °C for 72 h. Subsequently, cells were centrifuged for 10 minutes at 6000 rpm and 4 
°C. Cell pellet was frozen at -80 °C.
Pellet was subsequently resuspended in an appropriate volume of buffer A (20 mM Tris-HCl 
(pH 8.00), 500 mM NaCl, 10 mM Imidazole, 5 mM DTT, 10% (v/v) Glycerol) supplemented 
with protease inhibitor cocktail (SIGMAFAST™ Protease Inhibitor Cocktail Tablets, EDTA-
Free) and PMSF 1 mM. The cell suspension was lysed on ice trough sonication (24 rounds of 
30”; Amplitude 85%; Tip MS72; Bandelin Sonoplus HD2070 sonicator). The disrupted cell 
suspension was centrifuged for 1 h at 13000 rpm. The supernatant fraction was filtered with 
a 0.45 μM (MiniSart Syringe filter 0.45 μM) membrane to remove residual particles before 
chromatography. The supernatant was applied onto a His-Trap column (His-TrapTM FF 5 mL, 
GE Healthcare) equilibrated with buffer A. A wash step was performed using 5% of buffer B 
(20 mM Tris-HCl (pH 8.00), 500 mM NaCl, 500 mM Imidazole, 10% (v/v) Glycerol). Then, the 
protein was eluted with a linear gradient from 5% to 100% of buffer B over 10 column volumes. 
Fractions (0.5 mL) were collected and analyzed by SDS-PAGE. Fractions containing His-
hRAD51-BRC4 complex were pooled and then concentrated up to 0.5 mL using a concentrator 
(Amicon Ultra-15 Centrifugal Filter Units; cut-off 10 kDa; Merck-Millipore). The concentrated 
sample was injected onto a size exclusion chromatographic column equilibrated with buffer C 
(50 mM Tris-HCl (pH 8.00), 200 mM KCl, 0.1 mM EDTA, 2 mM DTT, 5% (v/v) glycerol). 
Fractions (0.5 mL) were collected and analyzed by SDS-PAGE.
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2.3.8 His-hRAD51 F86E-BRC4 complex: expression and purification
hRAD51 F86E-BRC4 complex was expressed in E. coli Rosetta2(DE3)pLysS cells. A saturated 
overnight culture in LB medium of Rosetta2(DE3)pLysS co-transformed with pET15b-His-
hRAD51 F86E and pET28a-BRC4 was diluted (1:1000) into a fresh TB-5052 auto-induction 
medium containing ampicillin (100 μg/mL) and kanamycin (50 μg/mL). The flasks were shaken 
at 200 rpm at 20 °C for 72 h. Subsequently, cells were centrifuged for 10 minutes at 6000 rpm 
and 4 °C. Cell pellet was frozen at -80 °C.
The His-hRAD51 F86E–BRC4 complex was purified as described in section 2.3.7.
Protocol for the expression and purification of His-RAD51 F86E-BRC4 complex
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2.4 Biophysical methods
Protein absorbance was measured at 280 nm using a UV-visible Nanodrop2000 spectrophotometer 
(Thermofisher) and protein concentration was calculated according to the Lambert-Beer law 
(Equation 2.2).
2.4.1 Protein and plasmid DNA quantification
Equation 2.2
where ε represents the extinction molar coefficient expressed in M-1 * cm-1; c is the protein 
concentration (mg/mL) and l is the light path in the sample (usually 1 cm).  ε was calculated 
for GST-hRAD51 and His-hRAD51 (Table 2.6) sequences reported in this thesis using 
ProtParamTool (www.expasy.org/protparam). Instead, it was not possible to measure the 
absorbance at 280 nm of His-BRC4 because there are no tryptophan, tyrosine or cysteine 
residues in the aminoacidic sequence of the peptide.
Table 2.6: Extinction molar coefficients (ε) and molecular 
weight of GST-hRAD51, His-hRAD51 protein and His-BRC4 
proteins.
Plasmid DNA concentration was obtained measuring the absorbance of the nucleic acids at 260 
nm, where they present their maximum of absorbance. 
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Two different sensor chips were used to immobilize the His-hRAD51 protein: a COOH5 and a 
His-Cap sensor chip (PALL Fortebio). The analyses were performed using a Pioneer FE SPR 
system (PALL Fortebio).
 His-hRAD51 (isoelectric point, pI = 5.42) was diluted in acetate buffer (pH = 5.00) to 
confer a significant positive charge to the protein and to promote its binding to the COOH5 surface. 
The low ionic strength in the buffer determined aggregation and consequently precipitation of 
His-hRAD51 in acetate buffer. Thus, it was not possible to perform the following step of protein 
immobilization on the sensor chip.
 A second attempt was performed using the His-Cap sensor chip. A solution of 500 μM 
NiCl2 was injected (10 μL; 10 μL/min) to promote the activation of the His-Cap surface. His-
hRAD51 diluted in the SPR running buffer (20 mM Hepes (pH 8.00), 250 mM KCl, Glycerol 
2%) was later injected over the sensor surface (50 μL; 10 μL/min) setting up a dissociation time 
of 1200 seconds. Regeneration of the surface was performed injecting a solution of 350 mM 
EDTA (75 μL; 30 μL/min) followed by the injection of 1 M imidazole (75 μL; 30 μL/min). This 
immobilization cycle reaction was repeated using four different His-hRAD51 concentrations 
(96.2 nM, 192 nM, 385 nM, 770 nM).
2.4.2 Surface Plasmon Resonance (SPR)
 His-hRAD51 was labelled with the NT-495 blue dye (NanoTemper Technologies) 
that binds the hRAD51 amine group of lysine residues. MST measurements simultaneously 
performed on 16 capillaries containing a constant concentration (80 nM) of NT-495-labelled-
His-hRAD51 protein and 16 different concentrations of BRC4 peptide or ARN22064 allowed 
to determine a concentration dependent MST binding curve. The highest BRC4 concentration 
2.4.3 Microscale Thermophoresis (MST)
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tested was 16 μM. The highest ARN22064 concentration used was 3 mM.
Measurements were carried out in MST buffer (20 mM Hepes (pH 8.00), 200 mM KCl, 0,1 mM 
EDTA, 5% (v/v) Glycerol). The ARN22064 compound required the addition of 5% DMSO in 
the MST buffer for solubility issues. 
 His-hRAD51 was also labelled with NT-647 red dye (NanoTemper Technologies) that 
binds the hexahistidine tail of the recombinant protein. MST measurements were performed 
as above described titrating a constant concentration (100 nM) of NT-647-HisRAD51 with 
16 concentrations of BRC4 peptide or each of the following compounds: ARN22142, E5, A6 
and F11. The highest concentrations used for the titrants were: 16 μM for BRC4, 6 mM for 
ARN22142 and 4 mM for E5, A6 and F11.
The MST buffer was supplemented with 5% DMSO to increase the solubility of the molecule 
and the fragments.
 A displacement assay was set up pre-incubating NT-647-labelled-His-hRAD51 (100 
nM) with ARN22142 (6 mM) or with E5 (1 mM). A constant concentration of complexes was 
then titrated as described above with BRC4. The highest BRC4 concentration used was 1 mM.
The MST analysis was performed using the NT.115 Monolith (Nanotemper Technologies). 
Binding curves were fitted using the Affinity Analysis software of Nanotemper Technologies to 
obtain binding affinity data. 
All NMR experiments were recorded at 25 °C with a Bruker FT NMR Avance III 600-MHz 
spectrometer equipped with a 5-mm CryoProbe QCI 1H/19F-13C/15N-D-Z quadruple resonance, 
a shielded z-gradient coil, and the automatic sample changer SampleJet NMR system with 
2.4.4 Nuclear Magnetic Resonance (NMR) 
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temperature controls. SPAM filter approach was used to characterize the chemical triazole class 
and the compounds ARN22064 and ARN22142 in buffer solutions. 1D 1H  water suppression 
in all proton experiments was achieved with the excitation sculpting sequence90; for a total 
number of 256 scans with a repetition time of 5 s. The two water selective 180° square pulses 
and the four PFGs were 2.5 and 1 ms in duration, respectively. WaterLOGSY experiments were 
acquired with 512 scans, 5 s repetition time, and 1.5 s mixing time.
 For the NMR Fragments screening a monodimensional 19F NMR spectrum and a R2 
filter experiment were recorded for a total of 64 scans with a repetition time of 5 s and proton 
decoupling during the acquisition period. For the R2 filter experiments a spin-echo scheme with 
total τ = 0.2 s was used. The data were multiplied by an exponential function corresponding 
to a line broadening of 1 Hz prior to Fourier transformation. The reference standard in the 19F 
spectra was CFCl3.
His-hRAD51 protein was concentrated up to ~ 5 - 10 mg/mL. Crystals of His-hRAD51 were 
grown with the hanging drop method in 96 well plates. Drops were prepared mixing equal 
volume (0.1 μL) of protein and reservoir solutions using a Mosquito Crystal Nanolitre Protein 
Crystallization robot (TTP Labtech). Crystal Screen and Crystal Screen 2 reagent kits (Hampton 
research) were used for protein crystallization.
2.4.5 Crystallization trials
His-hRAD51 crystallization trials
In a first set of experiments His-hRAD51 F86E-BRC4 complex was concentrated up to 26 
mg/mL. Crystals of His-hRAD51 F86E-BRC4 were grown with the hanging drop method in 
His-hRAD51 F86E-BRC4 crystallization trials
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96 well plates. Drops were prepared mixing equal volume (0.2 μL) of protein and reservoir 
solutions using a Mosquito Crystal Nanolitre Protein Crystallization robot (TTP Labtech). The 
following screening kits were used: ProPlex 1-96, JCSG-plus (Molecular Dimensions) and 
Crystal screen (Hampton research).
In a second set of experiments crystals of His-hRAD51 F86E-BRC4 complex were concentrated 
up to 13.5 mg/mL and grown as above described. The following crystallization screening kits 
were used: PEG/Ion, PEGRx, Crystal screen, Salt Rx (Hampton research), MCSG 1, MCSG 2, 
JCSG-plus, ProPlex 1-96 (Molecular dimensions).
58
The recombinant pure His-hRAD51 was incubated at 37 °C for one hour in the absence or 
presence of the BRC4 peptide in a 1:4 molar ratio. After incubation, protein samples were 
loaded onto a size exclusion chromatographic column (Superdex200 Increase 10/300 GL, GE 
Healthcare) equilibrated with the following buffer: 20 mM Hepes (pH 8.00), 250 mM KCl, 
EDTA 0.1 mM, Glycerol 5%, DTT 2 mM.
2.5 His-hRAD51 characterization
2.5.1 Size exclusion chromatography
Recombinant pure His-hRAD51 protein (1 mg/mL) was placed onto ultra-thin carbon film 300-
mesh copper grids and negatively stained in 0.2% - 0.5% uranyl acetate at pH 4.5 - 5.5. The 
samples were observed with a FEI Tecnai G2 F20 field emission gun transmission electron 
microscope (FEI Company, The Netherlands), working at an acceleration voltage of 80 keV and 
equipped with a 2k X 2K Gatan Ultrascan CCD camera (Gatan company, USA).
2.5.2 Negative staining transmission electron microscopy
His-hRAD51 (27 μM) was analyzed in DLS buffer (20 mM Hepes (pH 8.00), 250 mM KCl, 0.1 
mM EDTA, Glycerol 5%) and the particle size of His-hRAD51 was analyzed using a Zetasizer 
Nano Particle Analyzer (Malvern) at 25 °C using the standard operating procedure for size 
measurements. Data were collected at five different time points and expressed in terms of 
intensity distribution.
2.5.3 Dynamic Light scattering (DLS)
Materials and Methods
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Results and discussion
 The literature reports, describing the efforts to characterize through biophysical and 
structural approaches the human hRAD51 (hRAD51) protein and its mechanism of action, 
evidence that the expression of the recombinant full-length form of the protein is actually quite 
challenging. The first attempt to obtain a crystal of the full-length RAD51 was done by Shin 
et al.91 who tried to shed light on RAD51 interactions  able to control and affect homologous 
recombination (PDB: 1SZP). However, to achieve this aim, a humanized RadA protein (from 
Pyrococcus furiosus), homologous of hRAD51 (50% identity), was expressed.
Until today, the only published structure describing the hRAD51-BRC4 complex, (PDB ID: 
1N0W), was obtained by removing the first 97 amino acids of hRAD5151. The two proteins 
were purified as a single fusion protein linked by a flexible polypeptide sequence (Thr-Gly-
Ser)4Met-Gly. 
The N-terminal region of hRAD51 is highly conserved among eukaryotic RAD51 proteins, 
suggesting a specific role for this RAD51 region. This domain, highly disordered92, is relevant 
for protomer-protomer interaction through the polymerization motif 85-GGFTTATE-91. 
In 1999, Aihara et al.92 partially solved, by NMR, the structure of the N-terminal region of 
hRAD51 expressed as a truncated form of the first 114 amino acids. It consists of five short 
helices even though most of the peptide (residues 1 to 15 and 86 to 114) is disordered. 
Many of the issues encountered by researchers, working with the full-length hRAD51, come 
from the significant mobility of the N terminal region of the protein and from the protein natural 
tendency to self-aggregate that can lead to considerable protein instability. 
 In this research work, we face the challenge of expressing, purifying and characterizing 
the recombinant full-length hRAD51 in order to fully characterize the interaction of hRAD51 
with BRCA2 (BRC4) and clearly unveil the hot spots of the protein-protein interactions through 
biophysical characterization as well as X-ray crystallography. 
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The pGEX-4T-1-GST-hRAD51 vector for the expression in Escherichia coli (E. coli) of 
hRAD51 with a GST tag at the N-terminus was already available within the project. The GST 
moiety at the N-terminus was inserted to improve the solubility of the recombinant protein. 
BL21(DE3)pLysS E. coli cells were transformed with the above mentioned vector in order 
to express the heterologous protein. The expression protocol for hRAD51 in E. coli cells was 
pursued setting up a series of expression trials with variable parameters: temperature of bacteria 
growth before and after induction, concentration of IPTG and time of induction. 
 The protocol for GST-hRAD51 purification was optimized using two chromatographic 
steps: an affinity chromatography (GST-Trap column) and a size exclusion chromatography 
(Superdex200 column). 
Optimization of a protocol for the overexpression and purification of full-length hRAD51 
in bacteria cells
3.1 Expression and purification of GST-hRAD51
Affinity chromatography
Proteins extracted from the bacterial culture through cells sonication were loaded onto an 
affinity GST-Trap column (see Material and Methods). The elution chromatogram, resulted 
from the addition of 10 mM reduced glutathione to the elution buffer, is reported in Figure 3.1 
and it shows the presence of a single peak (fractions A6-A11) with a small shoulder (fraction 
A4).
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Figure 3.1: Chromatogram corresponding to the elution profile of the 
affinity chromatography (GST-Trap column).
Samples from the expression and first purification step of GST-hRAD51 were analyzed by 
SDS-PAGE (Figure 3.2).
Figure 3.2: SDS-PAGE of samples from the expression and first step of GST-hRAD51 purification: 
M: marker; proteins contained in a not induced (NI) and induced (I) bacteria sample; insoluble (P) 
and supernatant (S) fractions after bacteria cells lysis; loading input of the chromatographic column 
(Input); flow through (FT) and fractions (A4 and A6-A11) corresponding to the shoulder and main 
peak of the chromatographic elution (GST-Trap column) (see Figure 3.1). The black arrow indicates 
the full-lenght GST-hRAD51.
Even though a significant amount of insoluble fraction was detected after cell lysis, part of the 
protein was found in the soluble fraction. The recombinant protein binds the column resin as it 
can be observed by the presence, in the SDS-PAGE gel (pool fractions A6-A11), of a band at 
about 63 kDa, corresponding to the molecular weight of GST-hRAD51.
Results and discussion
63
Size exclusion chromatography
The A6-A11 fractions from the previous step of purification were pooled and concentrated. The 
obtained sample was then loaded onto a Superdex200 column (Material and Methods) in order 
to increase the purity of GST-hRAD51 and to evaluate the protein aggregation state. The size 
exclusion chromatographic profile (Figure 3.3) shows the presence of two peaks: the former is 
eluted in the column dead volume (8.43 mL), whereas the second one is eluted after 12.62 mL.
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Figure 3.3: Chromatogram corresponding to the Superdex200 elution 
profile.
Fractions corresponding to the peaks eluted from the gel filtration were analyzed by SDS-
PAGE (Figure 3.4). GST-hRAD51 (63 kDa) was the main component of the A2-A5 fractions, 
together with the presence of a weak band at 35 kDa. The latter band becomes, instead, the main 
constituent of the A11 and A12 fractions. 
The size exclusion chromatographic step, besides not significantly improving the purity of the 
expressed GST-hRAD51 protein (compared to the loaded sample), shows that the protein was 
purified as a high molecular weight oligomer (elution in the column dead volume), most likely 
as an already self-assembled protein.  
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Figure 3.4: SDS-PAGE analysis of samples after gel filtration. M: marker; 
Input: loading input of the Superdex200 chromatographic column; A2-A12: 
fractions of the Superdex200 elution. The black arrow indicates the full-lenght 
GST-hRAD51. 
The final protein yield, using the pGEX-4T-1-GST-hRAD51 construct, was 1.2 mg per liter of 
bacteria culture.
3.1.1 Degradation trials
In the attempt of improving purity and yield of the GST-hRAD51 protein we looked into the 
identity of specific proteins observed in the SDS-PAGE gel pattern of the peaks eluted from 
the two purification steps (Figure 3.5). Specific bands, as the one recurrently appearing at 35 
kDa in the SDS-PAGE, were cut from the gel, extracted and digested (Material and Methods). 
The products were analyzed by HPLC mass spectrometry (HPLC-MS) analysis. Interestingly, 
the presence of two truncated forms of GST-hRAD51 were identified with a molecular weight 
of 35.60 kDa and 35.46 kDa (data not shown). Identification of all the proteins present in the 
elution samples of the first chromatographic step, through HPLC-MS analysis, allowed the 
identification of two specific E. coli proteases (the ClpX protease and the HslU subunit, which 
form an ATP dependent protease complex with HslV93). These two proteases, expressed in E. 
coli bacteria, are most likely responsible for the specific protein truncation observed.  These data 
support our initial hypothesis i.e. purity and yield of the GST-hRAD51 protein are significantly 
affected by degradation issues.
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Figure 3.5: SDS-PAGE of samples (see Figure 3.3) eluted from affinity and size 
exclusion chromatographies and analyzed by HPLC-MS. Bands highlighted 
by red boxes were cut, extracted from the gel and analyzed by HPLC-MS to 
identify the amino acid sequence of the proteins corresponding to the bands. 
The black arrow indicates the full-lenght GST-hRAD51.
Degradation was confirmed storing the samples eluted from the affinity chromatography for 
one week at 4 °C. Comparison of SDS-PAGE gels of the same samples before and after storage 
showed that the band corresponding to the full-length GST-hRAD51 (~ 63 kDa) was converted, 
in time, into the band at about 35 kDa (not shown).
Protease inhibition trials
Previous studies have shown that  ClpX protease can be inhibited  by ZnSO4 or KCl
94, while 
HslV-HslU protease complex can be inhibited by the peptide vinyl sulfone, carboxybenzyl-
leucyl-leucyl-leucine vinyl sulfone95. Since the synthesis of the latter is quite prohibitive, 
several attempts were made to inhibit ClpX protease by the addition of ZnSO4 (1 mM) or KCl 
(300 mM) alone or in combination. 
Addition of ZnSO4 1mM or KCl 300 mM in the bacteria culture did not prevent protein 
degradation as shown in Figure 3.6 (western blot analysis). The recombinant protein is cleaved 
in different digestion products, independently from the addition of the two salts. 
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Figure 3.6: Western blot analysis using a polyclonal antibody against hRAD51 
of not induced (NI) and induced BL21(2DE3)pLysS/pGEX-4T-1-GST-hRAD51 
samples after addition in medium culture of ZnSO4 (1 mM) or KCl (300 mM) 
alone or in combination. The black arrow indicates the full-lenght GST-
hRAD51.
Bacteria growth and induction conditions were modified in an attempt to decrease the rate of 
degradation. Different parameters were modified: medium composition (ZYM-5052, LB, M9), 
temperature of growth and induction (20 °C or 37 °C).
Western blot analyses of the bacteria samples, grown in different culture media and induced 
at different temperatures, were performed. The analysis of bacterial cells grown in ZYM-5052 
medium showed a consistent degradation of GST-hRAD51 at 37 °C (digestion products with 
molecular weights between 37-50 kDa), whereas degradation was less evident when cells were 
grown at 20 °C (Figure 3.7a and b). 
Figure 3.7: Western blot analysis using a polyclonal antibody against hRAD51 to evaluate the 
proteolytic degradation of GST-hRAD51 in bacterial cells grown in ZYM-5052 medium at 20 °C (a) 
and 37 °C (b) after different incubation times (16 h; 20 h or 24 h). The black arrows indicate the 
full-lenght GST-hRAD51.
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The proteolytic degradation in cells grown in LB medium, irrespective of the induction time, 
was significant. In this case, as shown by western blot analysis (Figure 3.8), several digestion 
products of the full-length protein were detected. Lower degradation levels were observed in 
cells induced at 20 °C. Low degradation was also observed in bacterial cells grown at 37 °C in 
M9 medium and induced at 20 °C or 37 °C (Figure 3.8). 
Figure 3.8: Western blot analysis using a polyclonal antibody against hRAD51 to evaluate 
the proteolytic degradation of GST-hRAD51 in bacterial cells grown in LB medium (a) at 
different induction temperatures (20 °C or 37 °C) and times  (2 h, 3 h, 4 h or overnight) or 
in  M9 medium (b) at different induction temperatures (20 °C or 37 °C) and times (2 h or 
overnight). The black arrows indicate the full-lenght GST-hRAD51.
Even though the temperature of bacteria growth and induction affects the degradation of 
the overexpressed recombinant protein, it was not possible to inhibit GST-hRAD51 protein 
degradation significantly improving protein purity and yield. 
 The optimization of the protocol for the expression and purification of GST-hRAD51 
from BL21(DE3)pLysS cells presented several challenges. A significant amount of recombinant 
protein was lost in the insoluble fraction after cell lysis. GST-hRAD51 was expressed in low 
yield and the final protein preparation was not pure enough for further biophysical analysis.  
 Additional analyses showed that proteolytic degradation, operated by two specific 
endogenous E. coli proteases, was significantly affecting the purification. Several attempts were 
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made to inhibit the degradation process. The use of potential proteases inhibitors (KCl or Zn2+) 
or the modification of E. coli cells growth and induction conditions did not allow preventing 
the proteolytic events. 
 Taken together these experiments showed the need to change expression and purification 
strategy in order to produce a full-length pure hRAD51 protein in high yield. 
3.2 Expression and purification of His-hRAD51
Previous studies showed that proteolytic degradation, operated by endogenous proteases, can 
sometimes be avoided by changing both bacterial cell strain and vector96. Thus, a new attempt 
to express and purify the full-length hRAD51 was made by subcloning the gene sequence, 
coding for the hRAD51 protein, into a pET15b vector in order to overexpress hRAD51 with a 
His-tag at the N-terminal region (Materials and Methods). hRAD51 gene sequence (1107 bp), 
amplified by PCR reaction, and the pET15b vector (5708 bp) were double digested using BamHI 
and Bpu1102I restriction enzymes. hRAD51 gene sequence and pET15b vector, extracted and 
purified from agarose gel (Figure 3.9), were then ligated in order to obtain the pET15b-His-
hRAD51 construct.
hRAD51 subcloning into pET15b vector
Figure 3.9: Agarose gel of hRAD51 gene and pET15b vector (pET15b dig) after double digestion with BamHI and 
Bpu1102I enzymes. Not digested pET15b vector (pET15b not dig) was also loaded as negative control. 
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E. coli XL1-Blue cells were transformed with pET15b-His-hRAD51. Four different clones were 
selected for vector amplification. The DNA plasmid was extracted and quantified. Sequencing 
of plasmid DNA showed that only two pET15b-His-hRAD51 DNA plasmids had the right 
sequence (clone 1 and 2), whereas DNA plasmids from the other two clones (3 and 4) presented 
point mutations (data not shown). Hence, the vector pET15b-His-hRAD51 from clone 1 was 
amplified (Mini- and Maxi-Prep, kit Qiagen).
E. coli Rosetta2(DE3)pLysS cells were transformed with pET15b-His-hRAD51 (clone 1) 
for the expression of the protein of interest. The optimization of the protocol for hRAD51 
expression was pursued running different expression trials changing the following parameters: 
E. coli growth medium (LB medium; ZYM-5052 medium and TB-5052), temperature of E. coli 
cells growth and induction (20 °C and 37 °C), IPTG concentration (0.05 mM, 0.1 mM, 0.25 
mM and 0.5 mM), time of induction (2 h, 3 h, 4 h, 24 h, 32 h, 48 h, 56 h, 72 h). The optical 
density (OD600) of the bacterial culture was measured at the end of the induction to characterize 
bacteria growth under each condition. The amount of soluble protein, extracted under each set 
of conditions, was evaluated through SDS-PAGE gel of the lysed E. coli bacteria pellet. 
In Rosetta2(DE3)pLysS/pET15b cells grown in LB medium, the highest amount of His-hRAD51 
was detected after 3 h and 4 h of induction at 37 °C or after overnight induction at 20 °C, 
irrespective of the IPTG concentration used (Figure 3.10a, b and c). Thus, the time of induction 
plays a key role for the expression of His-hRAD51. The final OD600 for Rosetta2(DE3)pLysS/
pET15b cells grown in LB medium was 3.16 after 4 h and 37 °C, while OD600 was 3.3 after 
overnight induction at 20 °C. 
Expression trials
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In auto-induction media, ZYM-5052 or TB-5052, the maximum expression was observed after 
72 h of incubation, whereas only a small amount was produced after 24 h or 32 h (Figure 3.10c 
and d). Thus, the expression of protein was dependent on the time of incubation. The final OD600 
calculated for Rosetta2(DE3)pLysS/pET15b grown in ZYM-5052 and TB-5052 after 72 h was 
14 and 18.5, respectively.
a
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Figure 3.10: SDS-PAGE analysis of pET15b-His-hRAD51 expression in cells grown in different 
culture media. (a) and (b) samples from cells grown in LB medium at 37 °C for 1, 2, 3 and 4 h using 
different IPTG concentrations. Only the sample of cells grown in LB medium at 37 °C and induced 
at 20 °C overnight using 0.5 mM IPTG is reported in panel (c); (c) samples from cells grown in 
auto-induction medium ZYM-5052 for 24, 32, 48 , 56 and 72 h after inoculation; (d) samples from 
cells grown in auto-induction medium TB-5052 for 24, 32, 48, 56 and 72 h after inoculation. The 
black arrows indicate the full-lenght His-hRAD51.
The SDS-PAGE gels and bacteria growth parameters showed no relevant differences in the 
expression of His-hRAD51 in LB medium or in auto-induction media. However, the bacterial 
cells concentration, measured as optical density at 600 nm, was much higher in ZYM-5052 or 
TB-5052 medium than in LB medium.
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3.2.1 Degradation trials
Western blot analyses were performed to evaluate if degradation of His-hRAD51 protein also 
occurred in E. coli Rosetta2DE3pLysS cells grown under the different conditions described 
above (Figure 3.10). 
In the samples from cells grown in LB medium, a band at 40 kDa, corresponding to His-
hRAD51, was present in all samples. However, the products of protein digestion (bands at 
~37 kDa, ~35 kDa and ~33 kDa) were present as well, irrespective of the induction time and 
IPTG concentration. A low intensity band was observed at 37 kDa also in the “not induced” 
samples, because the polyclonal antibody against hRAD51 most likely recognizes also RecA, 
the endogenous bacterial homologous of hRAD51. The proteolytic digestion events are time 
dependent, in fact, degradation is more evident after 3 h, 4 h or overnight (Figure 3.11a, b and 
c) induction. 
Conversely, in bacterial cells grown in auto-induction media at 20 °C, the degradation events 
were less evident, in fact, in both media, only a degradation band at 35 kDa was detected 
(Figure 3.11c and d). An increase of the temperature of bacteria growth and induction enhances 
protein degradation.  
a b
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Figure 3.11: Western blot analysis of expression trials samples in different culture media using a polyclonal 
antibody against hRAD51. (a) and (b) samples from cell grown and induced in LB medium at 37 °C for 1, 2, 
3 and 4 h using different IPTG concentrations. Only the sample of cells grown in LB medium at 37 °C and 
induced at 20 °C overnight using 0.5 mM IPTG is reported in panel (c); (c) samples from cells grown in auto-
induction medium ZYM-5052 after 24, 32, 48, 56 and 72 h after inoculation; (d) samples from cells grown in 
auto-induction medium TB-5052 after 24, 32, 48, 56 and 72 h after inoculation. The black arrows indicate 
the full-lenght His-hRAD51.
In order to further test the effects induced by the degradation process, western blot analyses were 
performed on soluble and insoluble protein fractions extracted from bacteria cells grown in TB-
5052, in ZYM-5052 and LB media under the conditions were the highest protein expression 
was previously observed. The western blot analysis (Figure 3.12) showed an expected band at 
40 kDa, corresponding to His-hRAD51 in both soluble and insoluble protein fractions, after cell 
lysis. A degradation band at 35 kDa was detected in all insoluble protein fractions and in the 
soluble fraction of cells grown in ZYM-5052 medium. Products of digestion were, conversely, 
not detected in supernatant fractions of cells grown in LB and TB-5052 media.
Figure 3.12: Western blot analysis using a polyclonal antibody against hRAD51 to investigate the degradation 
events in soluble and insoluble protein fractions after cell lysis. M: marker; S: supernatant fraction after cell lysis; 
P: insoluble fraction after cell lysis. Cells were grown in TB-5052 and ZYM-5052 media at 20 °C for about 72 h 
and in LB medium at 37 °C and successively induced overnight at 20 °C. The black arrow indicates the full-lenght 
His-hRAD51.
TB-5052 ZYM-5052 LB
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These expression and degradation trials allowed selecting the optimal parameters for the 
expression of the full-length His-hRAD51 protein. Considering overexpression yield and level 
of protein degradation, and knowing that higher temperatures of induction can promote the 
association of overexpressed protein, the following optimal conditions for the expression of 
His-hRAD51 were identified: growth of Rosetta2(DE3)pLysS/pET15b-His-hRAD51 and 
induction at 20 °C in TB-5052 medium for 72 h.
 The protocol for the purification of hRAD51 was optimized with two different 
chromatographic steps: an affinity chromatography (His-Trap column) followed by an anion 
exchange chromatography (ResQ column). 
The total protein extract obtained from E. coli Rosetta2(DE3)pLysS-His-hRAD51 culture, 
grown in TB-5052 at 20 °C for about 72 h, was loaded onto a His-Trap column. The elution 
chromatogram (Figure 3.13) is an asymmetric peak obtained by setting a linear imidazole 
gradient (50 mM - 500 mM).  
Affinity chromatography
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Figure 3.13: Chromatographic profile of the affinity chromatography elution.
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Fractions corresponding to the expression and the first purification step of His-hRAD51 were 
analyzed by SDS-PAGE (Figure 3.14). A band at 40 kDa, corresponding to His-hRAD51 
protein, was detected in the insoluble and soluble protein fractions after cell lysis. A small 
amount of recombinant protein was also present in the column flow through. In the fractions 
of the main elution peak (G9 and H5) the band corresponding to the heterologous protein was 
present, whereas only a little amount of His-hRAD51 was detected in the shoulder (F4). 
Figure 3.14: SDS-PAGE analysis of His-hRAD51 expression and first step of purification. I: 
induced sample; P: insoluble fraction after cell lysis; S: supernatant fraction after cell lysis; FT: 
flow through; A13 and B3: fractions corresponding to the peak eluted after a wash step with 50 mM 
imidazole; F4-H5: fractions corresponding to the shoulder and main peak of the chromatographic 
elution (His-Trap column). The black arrow indicates the full-lenght His-hRAD51.
sonication His-Trap
The pooled fractions from the main His-Trap column elution peak were loaded onto a ResQ 
column. The elution (Figure 3.15), performed with a linear gradient from 200 mM to 1M KCl, 
generated a chromatogram with two main peaks (24 % and 50% of the linear gradient).
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Figure 3.15: Chromatographic profile of the anion exchange column elution. 
SDS-PAGE analysis (Figure 3.16) of the fractions eluted after anion exchange chromatography 
showed that the main elution peak (A6-A11 fractions) contained predominantly pure His-
hRAD51 (40kDa).
Figure 3.16: SDS-PAGE analysis of fractions eluted from the anion exchange 
chromatography. M: marker; input: loading input of the ResQ chromatographic 
column; A6-A11: fractions of the ResQ column elution. The black arrow indicates 
the full-lenght His-hRAD51.
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The purity of the obtained protein was further tested by concentrating the eluted protein and 
successively loading incremental quantities in a SDS-PAGE gel (Figure 3.17). Only one band 
corresponding to His-hRAD51can be detected in all samples.
Figure 3.17: SDS-PAGE analysis of increasing quantities (1, 2, 4, 6 and 8 
µg) of purified His-hRAD51. The black arrow indicates the full-lenght His-
hRAD51.
The final protein yield using the pET15b-His-hRAD51 vector was 15-20 mg per liter of bacteria 
culture.
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3.2.2 His-hRAD51 characterization
 Purified His-hRAD51 was analyzed by gel filtration, dynamic light scattering and 
electron microscopy to assess the aggregation state of the purified protein.
Size exclusion chromatographic experiments were performed in order to evaluate the state of 
His-hRAD51 oligomerization in the absence or presence of BRC4. 
The size exclusion chromatogram of the purified His-hRAD51 corresponds to the elution 
of a high molecular weight oligomer (peak in the column dead volume; Figure 3.18a). One 
hour incubation at 37 °C of His-hRAD51 with BRC4 peptide in a 1:4 molar ratio suggests the 
progressive dissociation of His-hRAD51 fibril into smaller oligomers up to the monomeric 
form (narrow peak eluted at 14.8 mL; Figure 3.18b).
The intrinsic tendency of hRAD51 to self-assemble into heptameric rings (fibrils), through 
a polymerization motif 85-GGFTTATE-91 located at the end of the N-terminal region of the 
protein, is already known91. Likewise, the tendency of hRAD51 to monomerize in the presence 
of BRCA2 (BRC4) has already been reported in literature97. The latter mechanism, which is 
activated when the stoichiometric ratio between the two proteins (hRAD51:BRC4) is higher 
than 1:1, seems to be critical in the disassembly process of the hRAD51 fibril after DNA repair 
has been terminated97.
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Figure 3.18: Superdex200 chromatogram of hRAD51 before (a) and after (b) incubation with BRC4 (1 h in 1:4 ratio).
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The electron microscopy (EM) image of freshly purified His-hRAD51, reported in Figure 
3.19, shows the fibrillar structure of His-hRAD51. This result confirms the natural tendency of 
hRAD51 to self-aggregate into fibrils
Figure 3.19: EM-negative stain image of His-hRAD51 fibrillar structure.
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The His-hRAD51 oligomer size was determined by dynamic light scattering (Figure 3.20). 
Data collected at five successive time points and expressed in terms of the intensity distribution 
showed a particle size with a mean diameter of 79.75 nm at 25 °C. The polidispersity index 
(PdI) calculated was 23%. DLS suggests that size distribution of recombinant His-hRAD51 is 
monodisperse. Based on DLS data reported by Esashi et al.98 for the monomeric hRAD51, the 
purified His-hRAD51, has a molecular diameter fourteen fold higher than hRAD51 monomer.
Figure 3.20: Particle size analysis of hRAD51 through DLS analysis. Data collected through five successive 
measurements.
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Biophysical characterization of hRAD51-hit molecules interaction through Surface 
Plasmon Resonance (SPR), Nuclear Magnetic Resonance (NMR) spectroscopy and 
Microscale Thermophoresis (MST)
The computational unit of our group, through a virtual screening campaign carried on the only 
available crystal structure of hRAD51 in complex with BRC4 (PDB 1N0W), has pursued the 
identification of potential inhibitors of the hRAD51-BRC4 interaction.
Compounds selected by virtual screening were synthesized by the chemistry group and further 
tested in biochemical and in cells assays.
One promising class of inhibitors contained a key triazole scaffold (Figure 3.21) in their 
structures. The chemistry unit performed a further structure activity relationship (SAR) analysis 
of the initial compounds. All the synthesized triazole derivative compounds were tested in 
biochemical assays designed to determine their ability to affect the hRAD51-BRC4 interaction99.
The most promising inhibitors were also tested in combination with olaparib in nonmutated 
BRCA2 cells by our collaborators from the University of Bologna. The simultaneous 
administration of the two molecules (new inhibitors and olaparib) allows to trigger 
pharmacologically induced synthetic lethality showing anticancer activity comparable to the 
one observed when olaparib is administered to BRCA2-defective cells99. 
3.3 Biophysical characterization of hRAD51-small molecules interaction
Figure 3.21: Triazole compounds identified by virtual screening protocol on X-ray crystal 
structures of hRAD51-BRC4 (PDB: 1N0W). 
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In order to confirm that the selected triazole inhibitors specifically target the protein-protein 
hRAD51-BRCA2 interaction, biophysical analyses were performed on the purified recombinant 
His-hRAD51 protein.
The most challenging step in a SPR experiment is frequently the setting up of a protocol for 
immobilization of the recombinant protein on a specific SPR sensor chip (see Appendix A4).  
 The first attempt that was performed was the immobilization of the His-RAD51 protein 
on a high density COOH5 chip, but the protein precipitated in the acetate buffer used to promote 
the interaction of His-hRAD51 to the sensor surface.  
 The second trial was performed using a His-Cap chip that is characterized by a 
oligoethylene glycol surface with nitrilotriacetic acid attached, which is activated by addition 
of nikel ions. His-hRAD51 binds to the sensor chip surface exploiting the hexahistidine tail 
located at the N terminal region of the protein. Four different concentrations of the protein were 
tested to achieve an optimal level of immobilization (Figure 3.22). Injecting His-hRAD51 770 
nM, a response of 3000 RU was obtained, showing a stable immobilization of the protein on the 
sensor surface.
3.3.1 Surface Plasmon Resonance (SPR)
RAD51 96.2 nM
RAD51 192 nM
RAD51 385 nM
RAD51 770 nM
Figure 3.22: Protein immobilization optimization using a His-Cap chip. Four different concentrations of His-hRAD51 
were tested:  96.2 nM (red curve), 192 nM (green curve), 385 nM (orange curve), 770 nM (blue curve). The His-Cap 
chip surface was regenerated with EDTA (350 mM) and imidazole (1 M).
Results and discussion
82
 Unfortunately, even though the experiment was successfully set up, the low solubility in 
aqueous buffer of the triazole molecules did not allow us to calculate their affinity and kinetic 
constant for the binding to His-hRAD51. The aqueous solubility of the triazole compounds, 
which have an average molecular weight of 490 Da, has been analytically calculated to be 
around 10 μM. The minimal stock concentration that we needed to perform SPR experiments 
and to detect the maximal response predicted (40 RU) was approximately 500 μM. The latter 
concentration was estimated from the EC50 values (about 50 μM) calculated for these molecules 
in the biochemical assays. At 500 μM concentration triazole compounds were not soluble.
 We further attempted to characterize the binding of triazole compouds to His-hRAD51 
using different techniques, such as MST and NMR that usually require lower compounds 
concentrations. However, also in these cases, the low solubility of these molecules did not 
allow to achieve the minimal concentration in solution required to detect the interaction with 
hRAD51. 
 Given the solubility issues encountered with some of the compounds under investigation, 
we characterized the triazole compounds (identity, purity and solubility) in buffer solutions 
by NMR spectroscopy. Moreover, their aggregation state was verified by SPAM Filter100 
experiments. Each triazole compound has been tested at 100 μM and 200 μM theoretical 
concentrations. All the triazoles showed very low solubility in buffer (from 1 μM up to 10 μM) 
and no aggregation effects were observed for this class of compounds. Due to the low solubility 
of the triazoles, it was not possible to detect their binding to His-hRAD51 by NMR. 
 Unfortunately, the solubility issues that we encountered in vitro with this class of 
compounds has become a critical issue for the overall project, thus the urgency to investigate a 
different class of compounds became at this point quite pressing.
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 Starting from different scaffolds and performing different structure activity relationship 
(SAR) studies, our computational and medicinal chemistry groups have recently identified 
other two classes of potential hRAD51-BRCA2 inhibitors: quinolinone pyrazoline derivative 
and the carboxyphenyl furane derivative, which have a higher solubility in aqueous solutions 
than triazoles. ARN22064, a representative of the quinolinone pyrazoline derivative class has 
already been reported in a publication of Acker et al.101, while the ARN22142, a representative 
of the carboxyphenyl furane derivative class has been newly synthesized in our group. The NMR 
characterization of ARN22064 and ARN22142 confirms a good solubility for both compounds 
(higher than 200 μM) in buffer solution while aggregation effects were not observed.
WaterLOGSY102 experiments were set up to test if the two new classes of compounds were in 
vitro able to bind the recombinant full-length His-hRAD51 protein.
WaterLOGSY experiments exploit the transfer of the bulk water magnetization to the chemical 
compound interacting with the protein (see Appendix A2.1). In a WaterLOGSY experiment the 
NMR signals of a chemical compound in solution are negative but, when the molecule interacts 
with a protein, its NMR signals become positive. We have tested ARN22064 and ARN22142 
at 100 μM concentration in the absence and presence of 1 μM full-length His-hRAD51. Figure 
3.23 shows the 1H 1D NMR spectra (bottom blue) of the aromatic portions of ARN22064 (left) 
and ARN22142 (right) and the two WaterLOGSY experiments in the absence (red) and presence 
(green) of His-hRAD51: both molecules bind the protein, i.e. their NMR WaterLOGSY signals 
become positive in the presence of His-hRAD51.     
3.3.2 NMR WaterLOGSY experiments
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ARN22064 ARN22142
Figure 3.23: 1H 1D NMR spectra (blue) of ARN22064 and ARN22142. WaterLOGSY experiments 
in the absence (red) and presence (green) of His-hRAD51 show the binding of the two compounds 
to His-hRAD51. Compounds concentration 100 μM, His-hRAD51 concentration 1 μM.
MST experiments were then performed in order to characterize and quantify the binding affinity 
of ARN22064 and ARN22142 for the full-length His-hRAD51 protein and to compare these 
data with the binding affinity of BRC4 for the protein (see Appendix A3). 
3.3.3 Microscale Thermophoresis (MST)
In a first set of MST experiments His-hRAD51 was labelled with the NT-647 dye, which 
specifically binds  the hexahistidine tail at the N terminal of His-hRAD51. NT-647 is a red 
fluorescent dye with excitation and emission maxima at approximately 650 and 670 nm, 
respectively. A constant concentration of NT-647-labelled His-hRAD51 (100 nM) was used to 
characterize the protein binding to the BRC4 peptide. A Kd of 63.30 ± 17.98 nM (Figure 3.24) 
was determined. 
The obtained affinity data were further confirmed by using a constant concentration of NT-495-
labelled His-hRAD51 (80 nM) (Figure 3.25). NT-495 is a blue fluorescent dye with excitation 
and emission maxima at approximately 493 and 521 nm, which is covalently bound to primary 
amines, mainly lysine residues of His-hRAD51 through amine coupling reactions.
The physiological hRAD51-BRC4 interaction is, as expected, strong.
His-hRAD51-BRC4 binding
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His-hRAD51-BRC4
His-hRAD51-BRC4
Figure 3.24: MST analysis of His-hRAD51-BRC4 binding. Titration curve of (NT-647)-His-hRAD51 (100 
nM) with increasing concentrations of the BRC4 peptide. Sigmoidal fitting curves were obtained using 
the Affinity Analysis software of Nanotemper Technologies. MST data are the average of three replicates.
Figure 3.25: MST analysis of His-hRAD51-BRC4 binding.  Titration curve of (NT-495)-His-hRAD51 (80 
nM) with increasing concentrations of the BRC4 peptide. Sigmoidal fitting curves were obtained using 
the Affinity Analysis software of Nanotemper Technologies. MST data are the average of three replicates.
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In a second set of experiments, a constant concentration of NT-647-labelled His-hRAD51 (100 
nM) was used to characterize the binding of the ARN22142 compound to the protein. Although 
the solubility of ARN22142 (6 mM) prevented us from using higher compound concentration 
and therefore to obtain a complete binding curve, it was possible to estimate a minimal Kd value 
of 2.71 ± 0.30 mM from the fitting of the collected data (Figure 3.26).
His-hRAD51-ARN22142 binding
His-hRAD51-ARN22142
Figure 3.26: MST analysis of His-hRAD51-ARN22142 binding. Titration curve of (NT-647)-His-hRAD51 
(100 nM) with increasing concentrations of ARN22142. Sigmoidal fitting curves were obtained using the 
Affinity Analysis software of Nanotemper Technologies. MST data are the average of two replicates.
A displacement assay was set up in order to verify if ARN22142 was able to prevent or interfere 
with His-hRAD51-BRC4 interaction. NT-647-labelled His-hRAD51 was pre-incubated with the 
highest soluble ARN22142 concentration in order to promote His-hRAD51-ARN22142 complex 
formation. BRC4 was successively titrated into the complex to verify its ability to displace the 
compound. From previous MST experiments, 16 μM BRC4 was able to saturated His-hRAD51 
(100nM) binding sites (see Figure 3.24 and 25); using the same BRC4 concentration to displace 
ARN22142 from His-hRAD51, no binding was detected (data not shown). 
 Thus, another displacement trial using a higher BRC4 concentration (1 mM) was 
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performed. Figure 3.27 shows that BRC4 binds His-hRAD51. The data obtained were considered 
sufficient evidence of displacement even though the binding curve was not complete. The 
complete binding curve would have required a significant amount of peptide without providing 
substantial additional information. 
His-hRAD51-ARN22142
+BRC4
Figure 3.27: MST displacement assay. Titration curve of (NT-647)-His-hRAD51 (100 nM)-ARN22142 
complex with increasing concentration of BRC4. Sigmoidal fitting curves were obtained using the Affinity 
Analysis software of Nanotemper Technologies. MST data are the average of three replicates.
As reported above, ARN22142 weakly interacts with His-hRAD51 (Kd 2.71 ± 0.30 mM).  Since 
pre-incubation of hRAD51 with ARN22142 induces a significant positive shift of the BRC4-
hRAD51 titration curve and therefore a decreased binding affinity of BRC4 for hRAD51, we 
assume that BRC4 displaces ARN22142 that binds hRAD51 in the same pocket. These data 
confirm the virtual screening analysis initially performed with this compound on the hRAD51-
BRC4 crystal structure available (1N0W).
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A constant concentration of NT-495-labelled His-hRAD51 (80 nM) was used to characterize 
the binding of the ARN22064 compound to the protein (Figure 3.28). A Kd of 98.81 ± 16.99 μM 
was determined, suggesting that ARN22064 compound weakly interacts with His-hRAD51.
His-hRAD51-ARN22064 binding
Figure 3.28: MST analysis of ARN22064 binding to His-hRAD51. Titration curve of (NT-495)-His-hRAD51 
(80 nM) with increasing concentrations of the ARN22064. Sigmoidal fitting curves were obtained using the 
Affinity Analysis software of Nanotemper Technologies. MST data are the average of three replicates.
The BRC4-His-hRAD51 binding (binding affinity in the nanomolar range) is stronger compared 
to the bindings of the two synthesized compounds to the protein (binding affinities in the micro 
and millimolar ranges). This result is quite straightforward comparing a “physiological” protein-
protein interaction to a synthetic molecule-protein interaction. Nevertheless, as reported above, 
the preventive binding of one of the molecules is able to weaken the protein-protein interaction 
therefore negatively affecting the target His-hRAD51-BRC4 interaction.
Results and discussion
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In parallel to the classical drug-like screening approach, above described, we decided to also 
pursue a fragment based approach (FBA) through NMR spectroscopy (Appendix A2). In Italian 
Institute of Technology (IIT) we have a home made local Environment of Fluorine (LEF) 
library103 constituted by about 900 fluorinated compounds with a molecular weight ranging 
from 100 to 350 Da and solubility in buffer higher than 400 μM.
 We performed a preliminary direct 19F-NMR ligand-binding screening against full-length 
His-hRAD51, using a portion of 185 fragments of our LEF Library. To identify the possible 
binders, we recorded transverse R2 filter fluorine experiments. The transverse relaxation rate R2 
is a very sensible parameter for these studies, due to the large Chemical Shift Anisotropy (CSA) 
of 19F nucleus and to the large exchange contribution. The observed response (Robs) in the R2 
filter experiments results in a line-broadening of the compound 19F-NMR signal when it binds 
to the target protein. 
 The fragments have been screened in mixtures of 20-25 compounds each, at the 
concentration of 40 μM, in the presence and absence of 1 μM full-length His-hRAD51. The 
knowledge of the chemical shift of the molecules forming the mixtures has allowed us to easily 
identify the binders. An example of the 19F-NMR screenings performed is reported in Figure 
3.29 where the 19F-NMR signals of compound mixtures in the absence of protein (black) and 
in presence of His-hRAD51 (red) are reported. Most of the signals do not show any significant 
change in the presence of the protein and therefore they do not interact with His-hRAD51. On 
the contrary, in the zoomed region, compound E5 shows a strong broadening of its 19F NMR 
signals in the presence of His-hRAD51, suggesting that E5 binds the protein. Out of the 185 
tested fragments, ten hits were identified.
3.4 Biophysical characterization of hRAD51-fragments interaction
3.4.1 NMR Fragment Based screening
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Figure 3.29: 19F-NMR screening of compound mixtures in the presence (red) 
and in the absence of His-hRAD51 (black).
 The binding was also confirmed testing the identified binders (hits) as single compounds in 
the same experimental conditions described above in the presence of a non-binder as internal 
negative control.
 In order to verify that the identified hits bind His-hRAD51 in the same pocket as BRC4, 
19F-NMR competition binding experiments were performed. The hits were tested in the absence 
and in the presence of protein and after the addition of 20 μM BRC4. The presence of competition 
between the compounds and BRC4 results in a sharpening of the 19F-NMR signal of the hit after 
BRC4 addition to the compound-His-hRAD51 mixture. Out of the ten hits identified by FBA, 
three fragments have been displaced by BRC4 (Figure 3.30). The NMR signals of compound 
B4 (negative control) do not show any variation in the presence of His-hRAD51 (red) as well 
as after the addition of BRC4 (blue) confirming that it does not interact with any of the two 
proteins. On the other end, the 19F signal of the three compounds E5, F11 and A6, shows a 
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significant line broadening effect and a decrease in signal intensity in the presence of His-
hRAD51 (red). The latter signals become sharp again after the addition of BRC4 suggesting a 
competition between the compound and the peptide for the binding to His-hRAD51.
Figure 3.30: 19F-NMR competition binding experiment. E5 (left), F11 (middle) and A6 
(right) were tested in the absence (black) and in the presence (red) of His-hRAD51, 
and after addition of BRC4 (blue) to the compound-His-hRAD51 mixture. B4 was used 
as negative control.
Microscale Thermophoresis analyses were performed in order to characterize the interaction 
between the fragments E5, F11 and A6 and His-hRAD51. A constant concentration of NT-647 
labelled His-hRAD51 (50 nM) was used to determine the compounds binding to the protein. 
Addition of F11 and A6 fragments to the protein did not induce any MST signal change, 
suggesting that these fragments do not interact with His-hRAD51 at the concentration tested 
(4 mM). On the contrary, MST analysis of the E5 fragment binding to His-hRAD51 clearly 
3.4.2 Microscale Thermophoresis analysis of the hit fragments
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confirmed the interaction of the small compound with the protein. A Kd of 1.23 ± 0.13 mM was 
calculated, suggesting that E5 weakly interacts with His-hRAD51 (Figure 3.31).
Figure 3.31: MST analysis of His-hRAD51-E5 binding. Titration curve of (NT-647)-His-hRAD51 (100 nM) 
with increasing concentrations of E5. Sigmoidal fitting curves were obtained using the Affinity Analysis 
software of Nanotemper Technologies. MST data are the average of three replicates.
His-hRAD51-E5
A displacement assay was set up to verify if the E5 fragment was able to prevent or interfere 
with His-hRAD51-BRC4 binding. The titration of BRC4 into the complex His-hRAD51-E5 
determined the displacement of the fragment as shown in Figure 3.32, confirming NMR data.
A significant amount of peptide would have been necessary in order to obtain the complete 
binding, without providing substantial additional information therefore we considered the 
reported data as clear evidence of the displacement.
The data show a decrease of the binding affinity of the peptide for His-hRAD51compared to the 
same experiment in the absence of fragment E5, suggesting that the fragment most likely binds 
in the same protein pocket as BRC4. 
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His-hRAD51-E5
+BRC4
Figure 3.32: MST displacement assay. Titration curve of (NT-647)-His-hRAD51 (100 nM)-E5 complex 
with increasing concentration of BRC4. Sigmoidal fitting curves were obtained using the Affinity Analysis 
software of Nanotemper Technologies. MST data are the average of three replicates. 
Results and discussion
94
In order to structurally characterize the full-length hRAD51, the His-hRAD51 protein purified 
as described above, was concentrated up to 5 - 10 mg/mL for crystallization screenings, which 
were carried out as described in the Material and Methods section. The conditions tested up to 
now did not allow to obtain crystals with good diffraction patterns. Even though from DLS data 
the purified His-hRAD51 sample is monodisperse, the fibrillar nature of the protein can be one 
of the possible reasons that make the crystallization procedure quite challenging.  
 In order to promote protein crystallization, we looked for a condition able to produce a 
monomeric, stable form of hRAD51. As we also reported above, the interaction of His-hRAD51 
with BRC4 in higher stoeichiometry than 1:1 induces hRAD51 monomerization. Moreover, 
it has been reported that mutation of phenylalanine 86 residue in glutamic acid (F86E), in 
hRAD51, can determine the production of monomeric protein, since it removes one of the key 
residues for protomer-protomer interaction (FXXA)51.
 Therefore, hRAD51 or hRAD51 F86E in complex with BRC4 can be suitable samples 
to obtain the crystal structure of the full-length protein and, at the same time, to characterize the 
interactions between the two proteins.
X-ray structural characterization of hRAD51-BRCA2 
The hRAD51-BRC4 complex was obtained by co-expressing the two proteins, i.e. by 
simultaneously transforming the two cDNAs with E. coli Rosetta2(DE3)pLysS cells in the 
presence of kanamycin and ampicillin antibiotics (Materials and Methods). The protocol for the 
purification of the hRAD51-BRC4 complex was optimized with two chromatographic steps: an 
affinity chromatography (His-Trap column) and a size exclusion chromatography (Superdex200 
column).
3.5 Expression and purification of hRAD51-BRC4 complex
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The total bacterial culture proteins extract, obtained after cells sonication, was loaded onto a 
His-Trap column. A linear gradient of imidazole (10 mM - 500 mM) in the elution buffer led to 
three elution chromatographic peaks.
Fractions eluted from the affinity chromatography were analyzed by SDS-PAGE gel (fig. 3.33). 
While the first eluted peak (fractions 13-20) contained mainly non-specific bound proteins, 
the second one (fractions 37 and 38) contained both hRAD51 and BRC4, and the last peak 
(fractions 65 and 66) was mainly constituted by hRAD51 alone.
Affinity chromatography 
Figure 3.33: SDS-PAGE of fractions eluted from the affinity chromatography. 13-20: fractions 
corresponding to the first eluted peak of the His-Trap column. 37-38: fractions corresponding 
to the second eluted peak of the His-Trap column. 65-66: fractions corresponding to the third 
eluted peak of the His-Trap column. The black arrow indicates the full-lenght hRAD51. The 
blue arrow indicates the BRC4 peptide.
The fractions containing the hRAD51-BRC4 complex were pooled, concentrated and 
successively loaded onto a Superdex200 column. The resulting chromatogram (Figure 3.34) 
showed a heterogeneous population with two dominant peaks: one in the column dead volume 
(7.5 ml) and the second one at the predicted molecular weight for the monomeric hRAD51-
BRC4 complex (14.59mL).
Results and discussion
96
Figure 3.34: Chromatogram of the Superdex200 colum elution 
profile.
The eluted fractions were analyzed by SDS-PAGE (Figure. 3.35). As expected, the monomeric 
peak (fractions D5-D8) corresponds to the hRAD51-BRC4 complex, while the rest of the 
chromatogram elution can be ascribed to hRAD51 alone in different oligomerization states.
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Figure 3.35: SDS-PAGE analysis of fractions eluted from gel filtration. 
Input: input loading sample; B7-D8: fractions of Superdex200 column 
elution.The black arrow indicates the full-lenght hRAD51. The blue 
arrow indicates the BRC4 peptide.
The co-expression of hRAD51 and BRC4 allowed obtaining a heterogeneous pool of hRAD51 
with different molecular weights and the heterodimeric hRAD51-BRC4 complex was only 
partially formed.
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A further attempt to obtain a homogeneous hRAD51-BRC4 complex led us to express and purify 
the hRAD51 F86E-BRC4 complex. The two proteins were co-expressed as described above for 
the non-mutated co-expressed complex. The purification protocol was again optimized in two 
chromatographic steps: an affinity chromatography (His-Trap column) and a size exclusion 
chromatography (Superdex200 column).
3.6 Expression and purification of hRAD51 F86E-BRC4 complex
The total protein extracted from a E. coli bacterial culture was loaded onto a His-Trap column. 
The elution was performed using a linear gradient from 10 mM to 500 mM imidazole resulting 
in the elution of two separate peaks. 
Fractions corresponding to the two eluted peaks were analyzed by SDS-PAGE (Figure 3.36). 
Only in the second peak, eluted at the highest imidazole concentration (fractions 28-36), the 
two proteins, hRAD51 and BRC4, are simultaneously present.
Affinity chromatography
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Figure 3.36: SDS-PAGE analysis of fractions eluted from the affinity 
chromatography. M: marker; 11-20: fractions corresponding to the first 
eluted peak of the His-Trap column; 28-36: fractions corresponding 
to the second eluted peak of the His-Trap column. The black arrow 
indicates the full-lenght hRAD51. The blue arrow indicates the BRC4 
peptide.
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The fractions containing the hRAD51 F86E-BRC4 complex were pooled, concentrated and 
successively loaded onto a Superdex200 column. The chromatogram reported in Figure 3.37 
evidences the presence of a small peak eluted in the dead volume of the column (fractions C2-
C4), and a main peak eluted at 15.55 mL.
Size exclusion chromatography
Figure 3.37: Chromatogram corresponding to the Superdex200 column 
elution profile.
Fractions corresponding to the main eluted peak were analyzed by SDS-PAGE (Figure 3.38) 
confirming that the hRAD51 F86E-BRC4 complex was pure and that the F86E mutation was 
critical to obtain a hRAD51 monomeric protein co-expressed with BRC4.
40
35
15
25
Figure 3.38: SDS-PAGE analysis of fractions eluted from Superdex200 
column. M: marker; Input: input loading; D6-E4: fractions of 
Superdex200 column elution. The black arrow indicates the full-lenght 
hRAD51. The blue arrow indicates the BRC4 peptide.
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Different crystallization trials were performed to obtain crystals from the purified hRAD51 
F86E-BRC4 complex.
The first trial was performed concentrating the complex up to 26 mg/mL and using three different 
crystallization screening kits in 96 wells plates (see Matherials and Methods).  
Since this first protein batch resulted to be too concentrated, i.e. significant protein precipitation 
in most of the crystallization wells was observed, the successive protein batches were 
concentrated only up to 13.5 mg/mL.
The protein storage buffer was also modified in order to improve complex stability. The buffer 
of the storage solution (Hepes, Tris, etc.) was modified as well as the NaCl concentration in the 
buffer.
Different crystallization trials were performed using several commercial kits (Materials and 
Methods). Basic crystallization kits for sparse matrix screenings were taken into consideration 
as well as more specific kits for biological macromolecules or macromolecular complexes.
Several weeks after sample plating large single crystals appeared in the following conditions:
- 0.1 M MES monohydrate pH 6.5, 1.6 M Magnesium sulfate heptahydrate (crystal Screen 2, 
condition 68, Hampton Research; Figure 3.39a)
- 0.2 M Potassium chloride, 0.05 M HEPES pH 7.5, 35% v/v Pentaerythritol propoxylate (5/4 
PO/OH) (Index screen, condition 56, Hampton Research; Figure 3.39b)
- 0.2 M Sodium sulfate decahydrate, 20% w/v Polyethylene glycol 3,350 (PEG/Ion screen, 
condition 33, Hampton Research; Figure 3.39c)
We do not know if the obtained crystals are salts or protein crystals, even though the long 
time taken for crystals formation (several weeks) and the crystals shapes suggest that they are 
protein crystals rather than salts. Moreover, even though the crystals morphology and sizes 
3.7 Crystallization trials of hRAD51 F86E-BRC4 complex
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are promising, we will find out if the crystals have enough long range internal order to allow 
the collection of good diffraction patterns to solve the complex structures only at the end of 
December, when they will be taken to the synchrotron for data collection.
We are anyway simultaneously screening a variety of different conditions to look for completely 
different crystallization set up that may result in crystals with different morphology and 
eventually diffraction patterns.
a cb
Figure 3.39: Optical microscope pictures of crystals grew from (a) crystal Screen 2 kit, condition 68 
(Hampton Research); (b) Index screen, condition 56 (Hampton Research) and (c) PEG/Ion screen, 
condition 33 (Hampton Research).
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Conclusions and perspectives
 Human RAD51 (hRAD51) is an ATP dependent recombinase that plays a key role in 
the homologous recombination pathway via interaction with BRCA2. Mutations in BRCA2 
protein impair its ability to bind hRAD51, leading to incompetent HR repair pathway. Recently, 
FDA has approved olaparib, a PARPi, for the treatment of ovarian cancer in BRCA2 defective 
patients. This therapeutic approach is based on the concept of synthetic lethality, which is 
a lethal phenotype deriving from a combination of two gene mutations. Thus, in BRCA2 
defective oncology patients, the administration of PARPi allows the simultaneous inhibition of 
two independent repair mechanisms, which result in an increase in cancer cells sensitivity to 
chemo- or radio-therapy. 
The key idea of our project is to trigger the synthetic lethality process through the administration 
of two different small molecules. This strategy can be used for the treatment of cancer in 
patients carrying nonmutated genes or when PARPi resistance is developed in BRCA2 mutated 
patients. Indeed, in the latter case, resistance is often due to restoration of nonmutated BRCA2 
or overexpression of hRAD51, which is reported in several tumors (i.e. breast, ovarian and 
prostate cancers).  
 Herein we optimized a protocol for the expression and purification of full-length 
hRAD51 in order to characterize the binding of hRAD51 and BRCA2 as well as of hRAD51 
and inhibitor molecules through biophysical techniques. 
 Initially, E. coli BL21(2DE3)pLysS cells were transformed using the pGEX-4T-1-
GST-hRAD51construct. Once the expression protocol was optimized, the protein was purified 
by two chromatographic steps: an affinity chromatography (GST-Trap column) and a size 
exclusion chromatography (Superdex200 column). When applied onto a Superdex200 column, 
GST-hRAD51 was eluted in the column dead volume, suggesting that it was purified as an 
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oligomer with high molecular weight. This is in agreement with the tendency of hRAD51 to 
self-aggregate. However, several issues occurred with this protocol: a significant amount of 
recombinant protein was present in the insoluble fraction after cell lysis, GST-hRAD51 was 
produced in low yield (1 mg of pure protein per liter of bacterial culture) and the recombinant 
protein was not pure enough for further biophysical analyses. HPLC-MS analyses also showed 
that purity and yield of GST-hRAD51 were significantly affected by proteolytic degradation 
mediated by endogenous proteases (ClpX and HslU-V proteases) of bacterial cells.  Attempts 
to inhibit or decrease the proteolytic degradation did not allow to avoid GST-hRAD51 
fragmentation. The expression and purification strategy was modified in order to produce a 
full-length pure hRAD51 protein in high yield.
 The gene coding for hRAD51 was subcloned from the pGEX-4T-1 vector to the 
pET15b vector to obtain a recombinant protein with a His-tag at the N terminal region. E. 
coli Rosetta2(DE3)pLysS cells were transformed using the new construct. The protocol for 
His-hRAD51 expression was optimized growing bacterial cells in TB-5052 medium for 72 h 
at 20 °C. The protein was then purified with two different chromatographic steps: an affinity 
chromatogram (His-Trap column) and an anion exchange chromatography (ResQ column) that 
allowed to obtain a pure hRAD51 in high yield (20 mg of recombinant protein per liter of 
bacterial culture). As expected, when applied onto a Superdex200 column, the protein was 
eluted in the column dead volume. DLS analysis suggested that the size distribution of the 
recombinant hRAD51 is monodisperse calculating a hydrodynamic radius of about 40 nm, a 
value fourteen times higher than the one of the monomeric form98. Furthermore, EM (negative 
staining) investigations on the pure recombinant protein confirmed the intrinsic tendency of 
hRAD51 to self-aggregate into fibrillar structures of high molecular weight. 
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 Compounds selected through a virtual screening campaign carried on the available 
crystal structure of hRAD51 in complex with BRC4 (PDB 1N0W) were synthesized by the 
chemistry group and further tested in biochemical and in cells assays. One promising class of 
hRAD51-BRCA2 inhibitors was constituted by molecules with a key triazole scaffold99. These 
compounds, tested on HR-proficient (BxPC-3) and -deficient (Capan-1) cells, showed their 
ability to trigger synthetic lethality when administered in combination with a PARPi (olaparib). 
The EC50 calculated for these molecules was in the micromolar (μM) range. The attempt of 
characterizing the binding of triazoles inhibitors to hRAD51 through biophysical techniques 
failed because of the low solubility (2 μM - 10 μM) of these class of molecules in aqueous 
buffer. In cell-based experiments, the solubility issue was probably overcome by the presence 
of carrier proteins (i.e. albumin) or other factors present in cells and in cells growth medium. 
Further SAR studies carried on the triazole compounds showed that improving the potency of 
these molecules was quite challenging. The low solubility of this class of compounds together 
with the issue of low potency effectively moved the group to look into new classes of inhibitors. 
The medicinal chemistry unit of the group identified two new classes of compounds: 
dihydropyrazole and carboxyphenyl furane molecules, respectively. The leading hit molecules, 
belonging to these two new classes of compounds ARN22064 and ARN22142, were investigated 
by nuclear magnetic resonance spectroscopy (NMR) and microscale thermophoresis (MST) to 
assess their binding to hRAD51. The binding of ARN22064 to hRAD51 and of ARN22142 to 
hRAD51, were characterized by a binding affinity of Kd = 98.81 ± 16.99 μM and of Kd = 2.71 
± 0.30 mM, respectively. As expected, these interactions are weaker than the physiological one 
between hRAD51 and BRC4 that we estimated to be Kd = 63.30 ± 17.98 nM. Nevertheless, a 
displacement assay, performed by MST, showed that ARN22142 was able to interfere with the 
Conclusions and perspectives
105
hRAD51-BRC4 protein-protein interaction, weakening the latter interaction. These data fully 
support our primary goal that is preventing hRAD51-BRCA2 interaction rather than displacing 
BRCA2 after binding. Even though we are still working to improve the affinity of the selected 
compounds for hRAD51, we do not aim at completely inhibiting hRAD51-BRC4 interaction 
since it would result in toxicological effects targeting also the HR pathway in non-pathological 
cells. We aim at modulating the HR pathway through inhibition of the hRAD51-BRCA2 
interaction relying of the fact that DSBs take place more often in cancer cells rather than in 
normal cells. The in-cell based experiments using pancreatic adenocarcinoma cells to verify 
the ability of the two compounds, ARN22064 and ARN22142, to impair the HR pathway are 
in process. These data, together with the obtained biophysical results, will highlight how these 
molecules specifically target the protein-protein hRAD51-BRCA2 interaction.
 The search for a new class of hRAD51-BRCA2 inhibitors was also carried out in 
parallel through a NMR fragment based drug discovery (FBDD) approach. An in house library 
of fluorinated compounds (MW ~ 350 Da) was screened by NMR for the identification of 
molecules able to bind the full-length hRAD51 protein. The identified hits were then tested by 
NMR for their ability to be displaced by BRC4 in their binding to the hRAD51 protein. Out 
of 185 fragments initially screened, three fragments, E5, A6 and F11, were selected through 
NMR experiments as hRAD51 binders able to be displaced by BRC4. The binding affinity of 
these fragments for hRAD51 was determined by MST. The MST analysis yielded a Kd of 1.23 
± 0.13 mM for the E5 fragment binding hRAD51. The E5 fragment weakly binds hRAD51. 
Nevertheless, E5 is able to affect the hRAD51-BRC4 interaction leading to a reduced BRC4 
affinity for hRAD51. Titration of A6 and F11 did not induce any signal change in MST binding 
curves, suggesting that these two fragments do not bind hRAD51 at the tested concentration (4 
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mM). Taking into account that the scaffold of the identified E5 fragment is quite different from 
the classes of molecules proposed by the classical drug-discovery process, we plan to pursue 
the optimization of this fragment and the successive development of a new molecule through a 
fragment based approach supported by NMR spectroscopy.
 As already mentioned, in the PDB the only crystal structure of the hRAD51-BRC4 
complex available (1N0W), is missing the N terminal portion of hRAD51 and a flexible 
polypeptide chain links the C terminal of hRAD51 and BRC4. The structure of hRAD51 
recombinase filaments, during catalysis of DNA-strand exchange, was recently solved by cryo-
EM58 and image processing with the support of the already published structures (1N0W, 1SZP 
and 1B22). Although these findings provided new structural insights on the full length hRAD51 
protein, they did not clarify how hRAD51 and BRCA2 interact and in particular, how the N 
terminal region of hRAD51 can be involved in the interaction with the BRCA2 protein. 
We did pursue the crystallization of the full-length hRAD51 as well as of the protein in complex 
with BRC4. The expression and purification protocols of the two complexes were optimized. 
hRAD51 was still partially aggregated in the co-expressed wild tipe hRAD51-BRC4 complex, 
while it was completely monomeric in the co-expressed hRAD51 F86E-BRC4 complex, thus 
suggesting that mutation F86E was essential to obtain a monomeric hRAD51 protein. Several 
crystallization screenings were performed both on the full-length hRAD51 and on the co-
expressed hRAD51-BRC4 and hRAD51 F86E-BRC4 complexes. Large, single crystals have 
been obtained from three crystallization screening conditions for the hRAD51 F86E-BRC4 
complex. Data will be collected at a synchrotron source in the next weeks.
 BRC3, one of the BRCA2 domains that shows the highest affinity for  hRAD51, interacts 
with the N terminal domain of hRAD51104. No structural details on this critical interaction are 
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yet available. We have recently cloned a BRC3-BRC4 construct that we will be co-expressed 
with the hRAD51 F86E protein and successively used in crystallization screenings. 
Crystallization trials are also in progress for hRAD51 F86E in complex with the recently 
identified soluble hit inhibitors.
 The present study has allowed the identification of hit molecules able to interfere with 
hRAD51-BRC4 starting from two different drug discovery strategies: a virtual screening and a 
fragment based approach. Biophysical analyses of hRAD51-BRC4 binding (Kd in the nanomolar 
range) shows how it is challenging to identify molecules able to prevent this interaction. 
Nevertheless, MST analyses of some of the tested molecules show their ability to interfere 
with hRAD51-BRC4 binding. In addition, structural information on the optimized full-length 
hRAD51 F86E-BRC4 complex and full-length hRAD51 F86E-inhibitors will clarify how 
these molecules are located with respect to the FXXA hRAD51 motif of protomer-protomer 
interaction. These data will be critical for the medicinal chemistry group to synthetize new lead 
molecules able to prevent the hRAD51-BRCA2 binding. 
The structure of the full-length hRAD51 F86E in complex with BRC4 and BRC3-BRC4 
will also clarify the role of the N terminal region of hRAD51 in the interaction with BRCA2. 
These findings will eventually allow the identification of new hotspots in the protein-protein 
interaction while providing new details about the HR pathway mechanism. 
The goal of this multidisciplinary project is the identification of small molecules, inhibitors of 
the hRAD51-BRCA2 interaction, to be administrated in combination with PARPi in patients 
carrying nonmutated genes or when PARPi resistance is developed. We are confident that our 
results will contribute to extend the possibility of exploiting this approach to other gene pairs 
involved in diverse synthetic lethality pathways.
Conclusions and perspectives
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The FBDD is based on the Fragment Based Approach (FBA) a screening methods developed 
in the 80’s-90’s to overcome some drawbacks of the High Throughput Screening. A potent 
inhibitor can be considered as the combination of fragments that bind different parts of the 
protein105;  the affinity of the whole molecule can be considered as the sum of its single parts106. 
The FBA advantage relies on the easiness in investigating the chemical space of a binding 
site using small molecules rather than bigger chemical entities. Indeed, Hann and coworkers107 
have demonstrated that the probability of randomly finding lead compounds strongly decrease 
with increasing molecular complexity, because small molecules can better fit the different 
binding pockets. Covering a chemical space can be better achieved by screening small fragment 
libraries rather than larger ones such as the one constituted by complex molecules. The hit rate 
for screening fragments is however higher than for larger molecules. 
 Currently, there is not a unique definition for a fragment. Fragments are typically 
compounds that follow the rule of three (RO3)108: MW ≤ 300 Da; No. HBD (Hydrogen Bond 
Donor) ≤ 3; No. HBA (Hydrogen Bond Acceptor) ≤ 3; No. ClogP (calculated LogP) ≤ 3. 
However, some fragment hits do not adhere to these restrictions indicating that this rule can be 
applied only as a guideline. The generation of a fragment library is based on the application of 
filters (i.e. RO3) to compounds from commercial or in house collections. 
 The low size of the fragments allows to check their properties in buffer solution before 
testing them. This can avoid issues related to false positive due to the aggregation of the 
compounds in solutions. On this purpose, Dalvit and coworkers100 developed a NMR approach 
to study the solubility, purity and aggregation state of the small molecules (SPAM), which has 
also been applied to the research work reported in this thesis.
 Due to their chemical simplicity and reduced functionality, active compounds (hits), 
A1 Fragment based drug discovery (FBDD)
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coming from FBA, usually show weak affinity for the target protein in the micro- milli-molar 
range. Fragments need therefore to be screened at high concentration; sensitive detection 
methods and structural information are also required to identify active fragments and improve 
their potency. The most used techniques are NMR, X-ray crystallography, SPR and fluorescence 
spectroscopy. Each approach presents both advantage and disadvantages.
 In this research work the FBDD was investigated by NMR, therefore only NMR-based 
screenings will be described in more details. 
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Diversity and robustness of NMR-based screening methods make these techniques highly 
interesting a tool for drug discovery. Only 5% of a fragment needs to interact with the partner 
to be revealed as a NMR hit, consequently NMR can detect hits with solubilities lower than 
their potencies109. In addition, NMR studies are characterized by high reproducibility and by 
the opportunity to check the quality of fragments (i.e. purity, solubility and aggregation state). 
 In NMR-based screenings two main approaches can be distinguished: “target-observed” 
and “ligand-observed” based techniques. The former provides structural information about the 
protein-ligand binding and allows the detection of the binding affinity, but it requires large 
amount of labeled proteins and it is limited by the size of the target proteins. The ‘‘ligand-
observed’’ based technique can be applied to a broader range of targets and unlabeled proteins 
at low concentration are used. Ligand-observed methods show changes in the NMR spectrum 
of a ligand upon interaction with the target protein. The most used ligand-observed methods 
are: WaterLOGSY102, 1H transverse relaxation time (T
2p
)110, STD111-113 and 19F NMR-based 
experiments114.
 In this thesis WaterLOGSY and 19F NMR-based experiments were used in order to 
investigate the binding of fragments (from in house collection), alone or in mixtures to hRAD51. 
A2 NMR-based screenings
WaterLOGSY (Water-Ligand Observation with Gradient SpectroscopY) is based on the transfer 
of magnetization from the protein to the small ligand (Figure A1) by using the bulk water 
magnetization. The water is selectively irradiated for a long period or selectively excited and 
followed by a long mixing time. During the irradiation time or the mixing time, the water 
magnetization is transferred to the protein via intermolecular NOE (Nuclear Overhauser Effect) 
and chemical exchange. The stored magnetization on the protein is transferred via intermolecular 
A2.1 WaterLOGSY
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NOE to the bound fragment. This NOE is negative (signals are conventionally displayed as 
positive in the WaterLOGSY spectra) due to the long tumbling correlation time of the protein. 
In addition to this mechanism one has to consider the transfer of bulk water magnetization to 
the fragment free in solution. This intermolecular NOE is positive (signals are conventionally 
displayed as negative in the WaterLOGSY spectra) due to the short tumbling correlation time of 
the fragment not complexed with the receptor. Therefore, the WaterLOGSY effect on a ligand 
is the weighted average of these two NOE effects. Owing to the fact that the ligand is not in 
high excess with respect to the protein and that the negative NOE is significantly larger in 
absolute value with respect to the positive NOE, the signals in the WaterLOGSY spectrum of 
a ligand in the presence of the protein are positive (Negative NOE). Thus, it is easily possible 
to discriminate the binders from non-binders. This method can also be applied to evaluate the 
possible aggregation of molecules.
Figure A1: Image adapted from Dalvit et al.102
A) The protein is shown with the buried cavities and the active binding site. Ligand is shown in the bound and free 
states. Excitation of bulk water (circles) is shown with a solid arrow and some of different magnetization transfer 
pathways are shown with dashed lines.
B) One-dimensional reference (upper) and WaterLOGSY (lower) spectra recorded for a 10-compound chemical 
mixture in the presence of 10 μM cdk2: positive and negative signals in the lower spectrum identify cdk2 interacting 
(binder) and not interacting molecules, respectively. 
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 In a recent study Dalvit115 demonstrated as 19F NMR, due to its very large dynamic 
range, is the most sensitive technique for detecting weak binders. 19F NMR, therefore, allows 
to test the compounds at concentration orders of magnitude lower than their affinities and to 
identify very weak inhibitors (mM) even if their solubility is low. 19F nucleus presents several 
advantages: 100% natural abundance, high sensitivity, favorable transverse relaxation and 
large dispersion of chemical shifts that allows the screening of large chemical mixtures without 
issues of signals overlapping. By 19F NMR spectroscopy it is possible to perform direct and 
competition (FAXS)116 binding screenings and functional biochemical screenings (FABS)117. 
Both binding experiments are based on R2 filter fluorine experiments. The transverse relaxation 
rate R2 is a very sensible parameter for these studies, due to the large Chemical Shift Anisotropy 
(CSA) of 19F nucleus and to the large exchange contribution. For a fragment weakly interacting 
with the receptor, the observed response (Robs), in the R2 filter experiments is given by the 
equation: 
A2.2 19F NMR-based experiments  
where the R2obs and Rb are transverse relaxation rates in the free and bound states, respectively. 
Pb and Pf are the fraction of ligand bound and free, respectively. The last term (δfree - δbound)
2 is the 
exchange term where δbound and δfree are the isotropic chemical shifts of the fluorine resonance 
of molecules in the bound and free states, respectively, and 1/K
−1
 is the residence time τ res 
of the ligand bound to the protein. The latter is responsible for the line-broadening and the 
consequent intensity decrease of the NMR signal observed when a compound binds to the target 
protein. The compounds can be screened in large mixtures or as single compounds. For each 
sample, two 19F R2 filter experiments are recorded; one in the absence and one in presence of 
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the target protein. A scheme of the FAXS experiment is shown in Figure A2. In the presence 
of a competitor, the line broadening of the 19F NMR signal of the binder becomes sharp again. 
FAXS experiments results very useful not only to screen non fluorinated compounds, but also 
to confirm the binding pocket of the identified hits: the displacement of the hits by the natural 
substrate and/or a known inhibitor suggests a competition event for the same binding site. 
Figure A2: Schematic diagram of the FAXS experiment. The broad signal of the spy 
molecule becomes sharp in the presence of a competitive ligand due to the displacement 
of the spy molecule from the receptor. (Taken from Dalvit et al.114).
n-FABS (n-Fluorine Atoms for Biochemical Screening) is a substrate-based screening assay in 
which the substrate or the cofactor of an enzyme is labelled with a fluorine moiety (Figure A3). 
19F-NMR spectroscopy is than used to detect and quantify the signal intensities of the substrate 
and of the enzymatic reaction products. The enzymatic modification of the substrate changes the 
electronic cloud of the F moiety resulting in different isotropic chemical shifts for the product 
and substrate fluorine signals. The high sensitivity of fluorine to the chemical environment 
allows the insertion of the F moiety even far from the reaction site. It is very important to notice 
that when using 19F-NMR, only the signals of the fluorinated molecules appear in the spectrum 
A2.3 n-Fluorine Atoms for Biochemical Screenings (n-FABS)
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and there is no interference between the enzymatic reaction and the detection system.
Figure A3: Schematic representation of FABS experiment. (Taken from Dalvit et al.114).
In the present study, WaterLOGSY and both direct-binding and FAXS experiments were 
performed on an in house fluorinated fragment library and on compounds identified by virtual 
screening campaigns on the X-ray structure of the hRAD51-BRC4 complex (PDB: 1N0W). For 
triazole compounds it was not possible to obtain any NMR spectrum, because the solubility of 
the small molecules was too low (<10 μM) to detect any signal.
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Microscale thermophoresis is a powerful tool to quantify biomolecular interactions. The 
measurement method is based on the directed movement of fluorescent molecules along a 
temperature gradient, an effect called “thermophoresis”. A local temperature difference ΔT, 
induced by an infrared (IR) laser localized on glass capillaries containing the fluorescent 
molecules, leads to a local change in molecule concentration (chot/ccold; depletion or enrichment), 
quantified by the Soret coefficient ST:
A3 Microscale thermophoresis (MST)
Thermophoresis depends on changes in size or on charge and solvation of shell molecules. 
As the buffer is kept constant, alterations in the thermophoretic depletion or enrichment can 
only arise from changes in the size, charge or solvation entropy of the fluorescent molecules. 
As the binding of a non-fluorescent ligand to a labeled molecule changes at least one of these 
properties, the binding can be quantified by measuring the change in thermophoresis at different 
ligand concentrations. 
 The instrument records the thermophoretic traces arising from the binding of a potential 
interactor mixed with the labelled molecule. Sixteen capillaries are simultaneously analyzed, 
each one containing the labelled molecule at constant concentration and the potential interactor 
at increasing concentrations. For analysis, the change in thermophoresis is expressed as a 
normalized fluorescence (ΔFnorm), which is plotted against molecular concentration to obtain a 
binding curve and consequently the Kd value of the interaction.
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Figure A4: Schematic representation of MST setup and experiments. A Monolith NT.115 instrument (NanoTemper 
Technologies Gmbh); B Representation of MST optics. IR laser scans up to 16 capillaries with a total volume of 
4 μL; C Signal from a MST experiment: a constant initial fluorescence from samples is detected. When laser is 
on, the T-jump is observed, due to a rapid change of in fluorophore properties in different temperature conditions. 
Subsequently, the thermphoretic of the molecules is detected in the temperature gradient. When laser is off, an inverse 
T-jump effect is detected; D Typical binding experiment in which it is possible to recognize the thermophoretic 
traces of molecules in bound and unbound state. Subsequently, the fluorescence traces are normalized and plotted 
vs ligand concentration to derive the Kd value; (Taken from Jerabek-Willemsen et al.
118).
In the present study the protein His-hRAD51 was labelled with two different dyes: the blue 
dye NT-495 that directly binds the amine group of lysine residues and the red dye NT-647 that 
labels biomolecules on hexahistidine tails. The choice of two different dyes arises from the 
intrinsic fluorescence of some compounds in blue or red light that interfere with MST analysis. 
The molecules arising from virtual screening analysis (triazoles, ARN22142 and ARN22064) 
and from NMR-based screenings (E5, A6 and F11) were analyzed through MST in order to 
investigate their ability to bind hRAD51.
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SPR is a physical phenomenon due to the interaction between light and matter. When a plane 
polarized light beam hits the interface metal-dielectric with an angle equal to an incident 
angle, called SPR angle, in condition of total internal reflection (TIR) it is partially adsorbed, 
generating a surface plasmon wave (Figure A5). The SPR angle depends on different factors, 
such as the thickness of the metal film or change in the refractive index due to the mass increase 
on the surface of the metal layer. In SPR instruments, the sensor consists of a glass substrate 
and a thin gold coating. The high sensitivity of modern SPR sensors allows to detect the binding 
of small molecules with protein targets. The former are dissolved in the buffer, the latter are 
usually immobilized through different chemical linkages to the surface of the biosensor.
A4 Surface Plasmon Resonance (SPR)
Figure A5: Schematic representation of a sensor in a SPR instrument. 
(Taken from https://www.fortebio.com/pioneer-spr-principles.html).
Injecting analytes over the chip, they can bind the protein target, causing a change in the SPR 
angle, proportional to the mass of bound ligand. Once the macromolecule is immobilized onto 
the chip (Rligand), the maximum response (Rmax) achievable during the binding of the ligand can 
be calculated according to the following equation:
Appendix
where MW
analyte
 and MWligand correspond to the molecular weight of analyte and ligand, 
respectively. n represents the stoichiometry of the reaction.
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R
max 
values higher than theoretic R
max
 are due to non-specific binding or to a super-stoichiometric 
interaction.
 The result from a SPR experiment is a sensogram, a plot of the change in SPR angle 
(Response) against the time that contains kinetic information of the binding detected (Figure 
A6). In a sensogram, the association phase in which the analyte binds to the macromolecule 
can be distinguished from the plateau, when the equilibrium is achieved (steady state). Finally, 
after the injection is stopped, the molecule starts to dissociate (dissociation phase). By fitting 
the curves corresponding to the association and dissociation phases, it is possible to calculate 
the kinetic constants kon and koff of the biomolecular interaction. The ratio of these two values 
provides the equilibrium constant Kd. 
Figure A6: Representation of a sensogram in which it is possible discriminate the 
different phases during a SPR experiment. (Taken from Ritzefeld et al.119).
 This technique allows to obtain measurements in real time and kinetics. In addition, 
the labelling of the molecules is not required. However, the immobilization of the proteins 
on the sensor surface can affect, in specific cases, the measured binding constants, since the 
immobilization may hinder peculiar binding pockets of the molecules on the protein. 
 Different sensor chips are available for the immobilization of the biomolecule of interest. 
Biosensors are low, medium or high capacity two or three dimensional surface chemistry that 
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can comprise different spacer (i.e. polyethylene glicol, dextran, carboxylated polysaccharide 
hydrogel) provided with different functional groups (i.e. carboxylic acids, nitrilotriacetic acid 
(NTA) functional groups, biotin functional groups) that allow to immobilize biomolecules 
exploiting different chemistries. 
 In the present study two different immobilization strategies were performed. In one case 
His-hRAD51 was immobilized via amine coupling, exploiting the presence of lysine residues 
on the protein surface available to form amine bonds (Figure A7). The protein immobilization 
step exploits electrostatics interactions between a positively charged His-hRAD51 onto the 
electronegative surface. However, since this step includes dilution of the protein in a solution 
with a pH below its isoelectric point, His-hRAD51 precipitated. 
Figure A7: Immobilization of a biomolecule via amine coupling onto a carboxyl surface 
chemically activated. (Taken from http://www.alfatest.it/keyportal/uploads/cooh-
chips-20130924.pdf ).
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A second immobilization trial of His-hRAD51 was performed using a His-Cap biosensor that 
employs the nitriloacetic acid (NTA)-nickel technique for protein attachment exploiting the 
His-tag binding (Figure A8). This method has the advantage of working in the optimal protein 
buffer condition and of providing a directed immobilization of His-tagged proteins. The protein 
was successfully immobilized, as shown in the results and discussion section.
Figure A8: Schematic representation of a His-tag biomolecule on a sensing surface 
exploiting the NTA-nickel technique; (Taken from http://www.alfatest.it/keyportal/
uploads/hiscap-chips.pdf).
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Glossary
5’ dRP: 5’ deoxyribose phosphate moiety
ADP: adenosine diphosphate
A-NHEJ: Alternative-Non Homologous End Joining pathway
AP: APyrimidinic or APurinic bases
ATM: Ataxia-Telangiectasia Mutated kinase
ATP: Adenosine TriPhosphate
ATR: Ataxia Telangiectasia and Rad3-related protein
BER: Base Excision Repair
BLM/DNA2: Bloom Syndrome RecQ Like Helicase/DNA replication helicase nuclease 2
bp: Base pairs
BRCA1: BReast Cancer-Associated 1
BRCA2: BReast Cancer-Associated 2
CDK: Cyclin Dependent Kinase
CHK1: CHeckpoint Kinase 1
CHK2: CHeckpoint Kinase 2 
ClogP: Calculated LogP
C-NHEJ: Classical Non-Homologous End-Joining
CSA: Chemical Shift Analysis
CSB: Chicago Sky Blue
CtBP: C-terminal Binding Protein
CtIP: C-terminal binding protein Interacting Protein
DBD: DNA Binding Domain
DDR: DNA Damage Response
dHJ: Double Holliday Junction
DIDS: 4,4’-DIisothiocyanostilbene-2,2’-DiSulfonic acid
DLS: Dynamic Light Scattering
DMSO: Dimethyl Sulfoxide
DNA-PKc: DNA Protein Kinases
DSB: Double Strand Breaks
DSBR: Double Strand Break Repair
DTT: DiThioThreitol
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Glossary
EDTA: EthyleneDiamineTetraacetic Acid
EM: Electron Microscopy
ERCC1: Excision Repair Complementing 1
Exo1: Exonuclease 1
FABS: Fluorine Atoms for Biochemical Screening
FANCF: Fanconi Anemia group F protein
FAXS: Fluorine chemical shift Anisotropy and eXchange for Screening
FBA: Fragment Based Approach
FBDD: Fragment Based Drug Discovery
FDA: Food and Drug Administration
G1: Gap 1 phase
G2: Gap 2 phase
GST: Glutathione S-Transferase
HBA: Hydrogen Bond Acceptor
HPLC-MS: High Performance Liquid Chromatography –Mass Spectrometry 
HR: Homologous Recombination
ICL: Interstrand CrossLink
IPTG: IsoPropyl β-D-1-ThioGalactopyranoside
IR: Ionizing Radiation
ITC: Isothermal Calorimetry
LB: Luria Bertani
LEF: Local Environment Fluorine
M: Mitosis
MDC1: Mediator of DNA damage Checkpoint protein 1
MES: 2-(N-Morpholino)EthaneSulfonic acid
MMEJ: Microhomology-Mediated End-Joining
MMR: MisMatch Repair
MRN complex: Mre11-Rad50-Nbs1 complex
MST: MicroScale Thermophoresis
MYC: MYC proto-oncogene protein
NER: Nucleotide Excision Repair
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NHEJ: Non-Homologous End Joining
NLS: Nuclear Localization Signal
NMR: Nuclear Magnetic Resonance
NOE: Nuclear Overhauser Effect
NTA: NitriloTriacetic Acid
OD: Optical Density
PARP: Poly(ADP)Ribose Polymerase
PARPi: PARP inhibitors
PCNA: Proliferating Cell Nuclear Antigen
PCR: Polymerase Chain Reaction
PDB: Protein Data Bank
PEG: PolyEthylene Glycol
PFG: Pulsed Field Gradient
PIKKs: PhosphatidylInositol 3-Kinase-like protein Kinase family
PNKP: PolyNucleotide Kinase 3’ Phosphatase
pRB: RetinoBlastoma protein
RFC: Replication Factor C
RO3: Rule Of three
ROS:  Reactive Oxygen Species
RPA: Replication Protein A
RU: Response Unit
S: Synthesis phase
SAR: Structure Activity Relationship 
SCID: Severe Combined Immunodeficiency
SDS-PAGE: Sodium Dodecyl Sulphate - PolyacrylAmide Gel Electrophoresis
SDSA: Synthesis-Dependent Strand Annealing
SOC: Super Optimal Catabolite repression 
SPAM: Solubility, Purity and Aggregation of the Molecule
SPR: Surface Plasmon Resonance
SSA: Single Strand Annealing
SSB: Single Strand Breaks
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SSBR: Single Strand Break Repair
STD: Saturation Transfer Difference 
TB: Terrific Broth
TDP2: Tyrosyl-DNA Phosphodiesterase 2
TopBP1: Topoisomerase-Binding Protein1
UV light: Ultraviolet light
WaterLOGSY: Water-Ligand Observation with Gradient SpectroscopY
WEE1: WEE1-like protein kinase
XLF: XRCC4 Like Factor
Glossary
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